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Directed Evolution of Cyclic Peptides for Inhibition of Autophagy 
Joshua Gray B.A. 
Advisory Professor: Steven Millward, Ph.D. 
In recent decades it has become increasingly clear that induction of 
autophagy plays an important role in the development of treatment resistance and 
dormancy in many cancer types. Chloroquine (CQ) and hydroxychloroquine (HCQ), 
two autophagy inhibitors in clinical trials, suffer from poor pharmacokinetics and high 
toxicity at therapeutic dosages. This has prompted intense interest in the 
development of targeted autophagy inhibitors to re-sensitize disease to treatment 
with minimal impact on normal tissue. We utilized Scanning Unnatural Protease 
Resistant (SUPR) mRNA display to develop macrocyclic peptides targeting the 
autophagy protein LC3.  The resulting peptides bound LC3A and LC3B—two 
essential components of the autophagosome maturation machinery—with mid-
nanomolar affinities and disrupted protein-protein interactions (PPIs) between LC3 
and its binding partners in vitro.  LC3-binding SUPR peptides re-sensitized platinum-
resistant ovarian cancer cells to cisplatin treatment and triggered accumulation of 
the adapter protein p62 suggesting decreased autophagic flux through successful 
disruption of LC3 PPIs in cell culture. In mouse models of metastatic ovarian cancer, 
treatment with LC3-binding SUPR peptides and carboplatin substantially reduced 
tumor growth after four weeks of treatment.  These results indicate that SUPR 
peptide mRNA display can be used to develop cell-penetrating macrocyclic peptides 
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Traditional drug design has focused primarily on the development of small 
molecules that occupy a specific region of physiochemical parameters of size 
(MW<500), hydrogen bond donors (HBD<5), hydrogen bond acceptors (HBA<10) 
and lipophilicity (LogP > 5) (1).  Commonly known as the “rule of 5” (RO5), these 
parameters of “druglikeness” emphasize the pharmacokinetic properties of oral 
bioavailability and cell permeability. Targets considered “druggable” (e.g. enzymes) 
typically have well-defined surface binding pockets that small molecules are able to 
access with high affinity and selectivity to modulate protein function within minutes to 
hours following administration. Protein families that inherently modify or interact with 
small compounds like G protein coupled receptors, nuclear hormone receptors, 
proteases, phosphatases, and kinases have all historically been amenable to 
drugging (2). Unfortunately, these easily druggable targets represent a relatively 
small fraction of target space.  Indeed, it is estimated that only ~10% of the human 
proteome is made up of druggable targets and that only half of those represent 
useful targets for treating disease (2). As of 2016, only 549 unique human protein 
targets have FDA-approved small molecule inhibitors (3).  The overwhelming 
majority of disease-related protein activities are considered undruggable as their 
critical interactions occur through interfaces of large protein surfaces (750-1500 Å2) 
that druglike small molecules simply lack the size to efficiently disrupt (4). 
Biologics (e.g. monoclonal antibodies and their variations) have seen 
development increase dramatically over the last two decades due to the ability of 
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these large compounds (~5-150 kDa) to inhibit protein-protein interactions (PPIs) by 
binding to large surface areas on targets with extremely high affinity and specificity. 
This class of compound however is inherently restricted to targeting extracellular 
proteins as the size of antibodies prevents them from crossing the cell membrane 
and accessing intracellular protein targets.  Although antibodies possess the 
requisite affinity and target selectivity for disrupting extracellular PPIs, their high cost 
of production and chemical instability complicates their translation from the bench to 
the clinic. 
Peptides occupy an important intermediate chemical space between small 
molecules and biologics that strongly positions them to become powerful therapeutic 
inhibitors of intracellular PPIs. With typical sizes between 5-30 AAs (~500-3500 Da), 
peptides possess sufficient surface area to achieve antibody-like binding to protein 
surfaces and inhibition of PPIs without becoming too large to categorically prohibit 
cell uptake. Protein interactions with peptides of 5-10 amino acids typically have a 
shared surface area >400 Å2 (5) which is thought to be sufficient for effective 
disruption of most PPIs. Historically, peptides have been dismissed as potential drug 
candidates due to a number of factors including susceptibility to proteolysis, lack of 
inherent cell permeability, and challenging library screening procedures. As we will 
see, cyclization and N-methylation of the peptide backbone provide answers to 
many of the cell permeability and serum stability issues inherent to using peptides as 
drugs against intracellular targets. Combined with recent advances in rapid 
screening and directed evolution technologies, cyclic peptides have enormous 
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potential to become a preferred molecular scaffold for the inhibition of intracellular 
PPIs. 
Scanning Unnatural Protease Resistant (SUPR) peptide mRNA display is a 
relatively recent advancement of the original mRNA display technology developed 
by Roberts and Stzosak that introduces macrocyclization, N-methyl amino acid 
incorporation, and protease screening (6). In this manner, libraries of trillions of 
unique compounds can be screened to produce cyclic peptide scaffolds that not only 
have superb affinity and selectivity for the target protein of interest, but are also 
nearly completely resistant to proteolytic degradation.  Cyclization, serves two 
purposes in the SUPR peptide architecture.  On one level, cyclization serves to 
constrain the three dimensional conformation of peptides, potentially freezing them 
in an active, target-binding state (7–9). Cyclization has also been shown to increase 
resistance to proteolytic degradation, possibly through increased conformational 
rigidity (10,11).  The incorporation of N-methyl amino acids has been shown by 
many investigators to drive proteolytic stability by introducing tertiary amides in the 
backbone (11,12).  Indeed, the incorporation of a single N-methyl amino acid has 
been shown to provide protection against proteolysis that extends several residues 
on either side of the incorporation site (13).   
My work is based on the hypothesis that several of the characteristics that 
define the SUPR peptide architecture will also impart cell permeability.  In the 
following sections, I will lay out some of the principles of cell permeability and the 
requisite physicochemical properties required to impart cell permeability to peptides.  
I will briefly review the growing field of cell permeable cyclic peptides with particularly 
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emphasis on the features of cell permeability that overlap with those found in SUPR 
peptides.  I will provide an overview of mRNA Display and SUPR mRNA display as 
well as a brief discussion of autophagy and the role of protein-protein interactions in 
this process.  Finally, I will introduce the LC3 protein, its PPIs, and its role as a target 
for SUPR peptide mRNA Display. 
Methods by which molecules cross the cell membrane 
Cellular plasma membranes are made up of a complex network of 
phospholipids arranged in a bilayer which protects the cell from its environment. The 
lipids that comprise the cell membrane consist of strongly hydrophilic head group 
attached to a hydrophobic lipid chain. These lipids are arranged in a double layer 
with the head groups exposed to the cell interior and exterior which isolates the 
hydrophobic lipid tails from the aqueous intracellular and extracellular environments 
(14). This arrangement creates a superb barrier between the extracellular space and 
the cell interior that is impermeable to all but a select few compounds. Internalization 
of molecules primarily occurs through three pathways: passive diffusion of 
moderately polar small molecules driven by a concentration gradient; endocytosis, 
the process of internalizing compounds adhered to the cell surface in vesicles made 
up of portions of the cell membrane; and active transport of molecules in a highly 
specific manner by ATP-activated protein transporters embedded in the surface of 
the cell membrane (15). With the exception of some classes of peptides that are 
actively transported, most peptides typically access the cytosol through passive 
diffusion or endocytosis. Some small di- and tri-peptides are actively transported by 
the proton-coupled oligopeptide transporter (SLC15) family of membrane transport 
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proteins (16,17) and some moderately sized (~8 residues) naturally occurring 
bicyclic peptides actively transported by the organic anion transporter polypeptide 
(OATP) family of transport proteins (18,19). As we will see, linear peptides lack 
many of the features that characterize highly cell permeable compounds. Significant 
modification—such as cyclization and incorporation of non-proteogenic amino 
acids—is typically required to achieve efficient entry into the cytosol. 
 Passive Diffusion 
Small, moderately polar molecules are among the few classes of compounds 
that are able to passively cross the cell membrane in an energy-independent 
manner (Figure 1A). Membrane transit from the aqueous environment of the 
extracellular space to the aqueous environment of the cytosol occurs in three steps. 
The molecule first partitions into the outer hydrophilic membrane surface, then 
transits the inner hydrophobic membrane core, and finally exits the inner membrane 
surface to access cell interior (20). Passive transport across the cellular membrane 
is driven by a concentration gradient across the membrane and therefore—ignoring 
any energetic costs of establishing the gradient—is an energy-independent process. 
The rate of diffusion across plasma membranes can be modeled simply by the 




𝒌𝒌𝒇𝒇  ×  𝑺𝑺 ×  ∆𝑪𝑪(𝒅𝒅)
𝒅𝒅 ×  𝒅𝒅𝑴𝑴𝟏𝟏/𝟐𝟐
 
Where dM/dt is the rate of transfer of compound across the membrane, kf is the 
compound’s membrane-water partition coefficient, S describes the surface area of 
the membrane, ∆C(t) describes the concentration gradient across the membrane, d 
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describes the thickness of the membrane, and MW1/2 is the square root of the 
molecular weight. The MW and kf are the two physical properties of the compound 
that define its ability to cross lipid bilayers. The membrane-water partition coefficient 
is the ratio of the concentration of a solute in water and and in lipid (such as octanol) 
when the two solvents are mixed and it is one measure of compound lipophilicity. 
Transit across membranes is directly proportional to kf, therefore strongly lipophilic 
compounds should more readily transit the hydrophobic membrane interior. 
Additional modeling studies have (20) identified desolvation as a critical aspect to 
initiation of partitioning of the membrane and that energy of desolvation strongly 
affects rate of transit across the membrane. Effectively this means that more 
lipophilic compounds pay a lower desolvation penalty when transitioning into the 
membrane interior. Druglike compounds are rarely strongly hydrophobic however, 
due to issues of solubility in the aqueous extracellular and intracellular 
environments. Successful therapeutic compounds must possess a delicate balance 
of hydrophobicity to drive cellular internalizations and hydrophilicity to maintain 
solubility. The rate of transfer is also inversely proportional to the MW of the 
compound meaning that smaller molecules will more diffuse more readily across cell 
membranes than larger molecules. If one plots this equation, it quickly becomes 
clear that the contribution of MW to permeability rapidly becomes asymptotic and 
above 400 Da the permeability penalties imposed by increasing MW effectively 




Figure 1: Diffusion and Endocytosis. A) Passive diffusion of molecules across the cell membrane is driven by a 
concentration gradient. Small, moderately polar molecules partition the outer membrane, diffuse through the 
membrane interior and access the cytosol. B) Endocytotic invagination of the cell membrane expends energy in 
the form of ATP to internalize compounds by pinching off portions of the membrane to form internal vesicles that 




          When we consider the Rules of 5 (RO5) for “druglike” compounds capable of 
passive permeation discussed earlier, it becomes readily apparent that most 
peptides—including cyclic peptides—are profoundly non-druglike. The RO5 provide 
convenient, easy to remember guidelines that predict whether a compound is likely 
to have acceptable passive permeability and oral bioavailability. With an average 
molecular weight of approximately 110 Da per amino acid, cyclic peptides begin to 
push the size boundaries of druglikeness in as few as five residues. On top of this 
fact, each peptide bond contributes 1 hydrogen bond donor (HBD) and 2 hydrogen 
bond acceptors (HBAs) before consideration of the chemical composition of the 
amino acid side chains. Based on these two factors, the RO5 guidelines predict that 
both cyclic and linear peptides containing 5 or more amino acids should not be cell 
permeable by passive diffusion.  
For the most part this prediction is accurate, though there are notable 
exceptions in which cyclic peptides—both naturally occurring and synthetic—readily 
diffuse through the cell membrane. A key feature commonly found passively 
permeable cyclic peptides is the elimination of backbone HBDs through Nα-
methylation of backbone amines and extensive intramolecular hydrogen bonding 
(15,21). Hydrogen bonds between backbone amide protons and water typically have 
a free energy of around 1 kcal/mol which is imposed as a desolvation penalty that 
must be paid when partitioning the membrane (22,23). Incorporation of N-
methylation and intramolecular hydrogen bonds reduces the number of uncapped 
polar N-H groups in the peptide backbone that would require desolvation in order to 
achieve diffusion into the hydrophobic membrane interior (24).  The inclusion of at 
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least one depsipeptide linkage has also been shown to contribute to passive 
permeability in a similar manner to N-methylation (21) as the replacement of an 
amide group in the peptide backbone with an ester linkage eliminates an HBD. 
However, the introduction of ester bonds in the backbone may impair the 
translatability of depsipetides into effective clinical therapeutics due to serum stability 
issues introduced by susceptibility to ester hydrolysis. Stability studies of cyclic 
lipodepsipeptides in human serum revealed that ~65% of lipodepsipeptide was 
degraded in 24 hours—primarily due to hydrolysis of the ester bond—compared to 
no significant degradation of the control peptide which contained only amide 
backbone bonds (25).  
Small tetramer and pentamer cyclic peptides and depsipeptides such as 
tentoxin and romidepsin largely obey the RO5 size restrictions and also reduce HBD 
load through N-methylation, depsipeptide linkages, and intramolecular hydrogen 
bonding (21,26,27). The most prominent example of a large cyclic peptide the 
passively permeates the cell membrane is Cyclosporine A (CsA), an 11-mer cyclic 
peptide immunosuppressant that possesses both excellent oral bioavailability and 
cell permeability despite violating the RO5 guidelines on size and HBD/HBAs 
(Figure 2A)(28). CsA contains 7 N-methyl amino acids and can undergo a 
significant conformational shift to reduce the number of backbone HBDs exposed to 
solvent. In aqueous environments, CsA adopts an “open” conformation which allows 
its backbone amides to interact with water molecules or its intracellular target, 
cyclophilin. When entering the cell membrane, CsA adopts a “closed” conformation 
in which all of its backbone amides that are not N-methylated participate in 
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intramolecular hydrogen bonds which dramatically reduces its polar surface area 
(29). Interestingly, Cyclosporine E (CsE)—a variant of CsA that lacks N-methylation 
of Val11—does not completely deplete HBDs in the peptide backbone and 
conformational changes occur at a 10-fold slower rate than CsA.  This results in 
dramatically reduced cellular permeability and highlights the extent to which 
desolvation penalties drive membrane permeability by passive diffusion (29). Other 
large cyclic peptides such as enniatin B, patellamide C, and the PF1171 family of 
peptides that exhibit strong passive permeability all completely deplete backbone 
HBDs through a combination of N-methylation and intramolecular hydrogen bonding 
(21,30).  
Endocytosis and Macropinocytosis 
Endocytosis is the process of internalizing membrane proteins, lipids, and 
extracellular molecules from the exterior surface of the cell by invaginating the cell 
membrane and forming an internal vesicle (Figure 1B)(31). Once internalized the 
vesicle is transported to intracellular compartments (i.e. lysosomal or golgi 
compartments) for downstream processing. While clathrin-mediated endocytosis has 
been studied extensively in the literature (32), other mechanisms of receptor-





osis represents one 
of the more well-
studied forms of non-
clathrin-mediated 
endocytosis.  Unlike 
endocytosis which 
proceeds through 




formation of large 





outwards from the 
cell surface (33,34). Activation of membrane growth factor receptors such as EGFR 
is known to initiate membrane ruffling and, as a consequence, highly elevated 
macropinocytic activity is often observed in cancer cells that overexpress growth 
factor receptors (35). Macropinocytosis is non-selective in its cargo uptake and its 
Figure 2: Examples of various constrained cyclic peptides. A) Cyclosporine 
A, a naturally occurring 11mer peptide contains 7 N-methylated backbone 
residues (red) and can undergo a conformational shift, forming extensively 
internal hydrogen bonds in the peptide backbone allowing it to passively diffuse 
through the hydrophobic membrane interior. B) An example SUPR peptide 
produced by a selection against HER2 (Fiacco 2016). SUPR peptide mRNA 
display produces cyclic peptides that combine both N-methylation (red) and 
macrocyclization through a hydrophobic crosslinker (blue) which may impart 
intrinsic cell permeability. C) Example stapled peptide ATSP-7342, this peptide 
utilizes a hydrophobic crosslinker to enforce α-helical structure. ATSP-7342 
efficiently accesses the cytosol through endocytosis and inhibits MDM2/MDMX 
PPIs. The presence of a hydrocarbon staple appears to be critical for cell 
permeability.  A modified version of this stapled peptide (ALRN-6924) is currently 
in Phase-II clinical trials for the treatment of several types of cancer. 
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vesicles are typically much larger than other endosomal vesicles. Despite this, 
macropinocytotic vesicles undergo very similar processing through the endosomal 
and lysosomal compartments (36).  
Both receptor-mediated endocytosis and macropinocytosis are subjects of 
interest as tools for delivering exogenous compounds to the cell interior, particularly 
in the case of large molecules and nanomaterials that cannot access the cell interior 
through passive diffusion or active transport (37). Macropinocytosis in particular has 
been studied extensively as a mechanism to deliver therapeutics semi-specifically to 
cancer cells, due to the tendency of these cells to be highly macropinocytotic by 
virtue of growth factor receptor overexpression (36). It is currently believed that 
cytosolic access following endosomal or macropinocytotic uptake is limited primarily 
by escape from the endosome interior rather than initial uptake efficiency. 
  The discovery in the early 1990s of two peptides—the transactivator of 
transcription domain of HIV (TAT, GRKKRRQRRRPQ) and Antennapedia 
homeodomain of Drosophila (penetratin, RQIKIWFQNRRMKWKK)—which were 
found to cross the cell membrane through endocytic uptake initiated the study of so-
called cell-penetrating peptides (CPPs)(38,39). This class of heavily cationic and 
amphipathic peptides are readily taken up into the cell by endocytosis and 
subsequently escape the endosomal vesicles to access the cytosolic milieu. As of 
early 2020, more than 1700 unique peptide sequences have been classified as 
CPPs according to CPPsite 2.0, a database that tracks CPPs in the literature (40). 
While the exact mechanisms by which CPPs access the cytosol remains a topic of 
debate, it is consensus agreement that internalization of CPPs occurs through 
21 
 
endosomal uptake initiated by association with the outer plasma membrane. 
Cationic CPPs such as TAT and polyarginine depend on coulombic interactions 
between the positively charged side-chains of basic amino acids—primarily arginine 
and lysine—and the negatively charged surfaces of cellular membrane (41,42).  It 
has also been established that the association of the guanidinium sidechains of 
arginine with heparan sulfate drives initiation of endocytosis, providing evidence that 
CPPs are active initiators of endocytosis. Uptake of these peptides by endocytosis 
may also benefit from normal membrane recycling activities (43,44). Like cationic 
CPPs such as TAT, amphipathic peptides such as penetratin and RW9 
(RRWWRRWRR) form hydrogen bond associations with the surface of the outer cell 
membrane but also undergo hydrophobic interactions via sequestration of aromatic 
side-chain residues into the lipid bilayer (45,46).  
Following internalization of the endosome, CPPs must escape from the 
endosomal-lysosomal compartment. While it is has been established that CPPs do 
escape endosomes, escape efficiency for linear CPPs is generally very poor and the 
vast majority of linear CPPs remain trapped in the endosome and are eventually 
degraded without ever gaining access to the cytosol (15). Proposed mechanisms of 
escape have been poorly studied until very recently and evidence supporting 
hypothesized mechanisms of endosomal escape remains sparse. One of the more 
prominent theories of endosomal escape posits that the CPP associates with the 
interior surface of the endosome as it matures and acidifies, generating transient 
toroidal or barrel stave pores in the membrane through which the CPP escapes by 
diffusion into the cytosol (47,48). However, this model cannot fully explain why some 
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CPPs are able to facilitate the transport of large macromolecules (e.g. nucleic acids 
and nanoparticles) out of endosomes (49,50). 
Until very recently, CPP research has focused nearly entirely on linear 
peptides. According to CPPSite 2.0, a database that tracks the CPP literature, nearly 
95% of unique CPP sequences are linear peptides (40). The uptake efficiency of 
linear CPPs—defined as the concentration of peptide in the cytosol versus the 
extracellular concentration—ranges from 0.2-4.0%. This low rate of uptake is 
thought to be driven largely by poor endosomal escape rather than by inefficient 
endosomal loading (51). Cyclic CPPs, on the other hand, have demonstrated the 
potential for significantly higher uptake efficiencies—in some cases more than two 
orders of magnitude higher—than those observed in linear CPPs. Studies of cyclized 
variants of TAT, polyarginine, amphipathic polarginine peptides incorporating 
tryptophan groups, and many other cyclic CPPs have demonstrated several-fold 
higher uptake rates in cyclic variants of the peptide compared to linear formulations 
(52–54). The Pei group has designed a family of amphipathic, cyclic nona-peptides 
combining two aromatic, hydrophobic residues (phenylalanine, 2-naphthylalanine) 
and four arginine residues that have achieved cytosolic delivery efficiencies between 
20-120%—as much as 2 orders of magnitude greater than linear TAT—and show 
evidence of delivering large macromolecules and fluorescent proteins to the cytosol 
with similar efficiency (55–57). Interestingly these molecules appear to escape from 
early endosomes rather than late endosomes as TAT most other linear CPPs do.  
The combination of conformational stabilization through macrocyclization and 
amphipathicity seem to be critical physiochemical features that drive efficient access 
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to the cytosol by CPPs. A potential explanation for this phenomenon may be that the 
bottleneck for cytosolic access lies in endosomal escape rather than initial 
endosomal uptake; traditional cationic CPPs like TAT appear to have similar initial 
endosomal uptake to cyclic, amphipathic CPPs despite dramatically lower cytosolic 
access efficiencies (15). It has been proposed that pore formation in endosomes 
requires association with the inner endosomal membrane by cationic guanidinium 
groups and simultaneous, orthogonal insertion of hydrophobic side chains into the 
membrane (57). The enhanced backbone rigidity enforced by macrocyclization or 
hydrocarbon stapling may reduce conformational entropy and cause amphipathic 
cyclic peptides to more consistently adopt conformations capable of achieving both 
hydrophilic and hydrophobic interactions with the endosomal membrane than linear, 
cationic and amphipathic CPPs can achieve.  This implies that the conformational 
restrictions required for endosomal release may be different from those required for 
target engagement. Thus, CPPs are perhaps best employed as cell delivery vectors 
rather than as a component of a target-binding scaffold. 
While eminently useful for basic research and chemical biology applications, 
the highly cationic nature of CPPs has proved a sizeable hurdle to their translation 
into clinical use. In vivo biodistribution studies of common CPPs like TAT, penetratin, 
and polyarginine reveal that these compounds initially bind strongly to the 
vasculature local to the site of administration followed by rapid clearance through the 
liver. In some cases, 90% liver uptake was observed in as little as 30 minutes 
(58,59). This rapid accumulation of compound in the liver is known to be associated 
with acute liver toxicity at clinically relevant doses (58). Despite these issues that 
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impair the ability to translate CPPs into clinical use, they have contributed 
expansively to the understanding of how to design therapeutic peptides with 
enhanced cell permeability.  
There is evidence that stapled peptides—a special class of cyclic peptides in 
which the side chains of the i, i+4 or i, i+7 residues are crosslinked with a 
hydrocarbon linker to enhance α-helical structure and increase protease 
resistance—are cell permeable at least in part through endosomal uptake and 
escape. Hydrocarbon stapling typically occurs between the i,i+4 or i,i+7 residues 
because these spacings correspond to one or two α-helical turns respectively (60). 
Bridging the side-chains at these positions with a hydrophobic crosslinker 
significantly reinforces the α-helical structure of the macromolecule. An exhaustive 
study by Verdine and colleagues on the uptake mechanisms of over 200 
hydrocarbon stapled peptides and CPPs found that cell permeability was correlated 
with formal positive charge and that cellular uptake was abrogated in CHO cells 
deficient in sulfated proteoglycans (61). Their studies suggest that hydrocarbon 
stapled peptides access the cytosol primarily through clathrin/claveolin-independent 
endocytosis triggered by association with negatively charged membrane 
components, similar to traditional cationic and amphipathic CPPs. Uptake efficiency 
was also found to correlate strongly with the extent of helical stabilization. When 
stapled in different locations, a peptide derived from the BH3 domain of the BID 
apoptotic effector protein exhibited differing levels of α-helicity by circular dichroism 
(CD) spectroscopy and significantly lower endosomal uptake was associated with 
peptide variants that had less-stabilized helical structure (62). Several stapled 
25 
 
peptides have been shown to be successful at crossing the cell membrane to disrupt 
PPIs, most notably in the case of inhibitors of the MDM2/MDM4:p53 interaction.  
ALRN-6924—a stapled peptide mimetic of the MDM2/MDM4 binding region of p53—
efficiently permeates cell membranes to mediate its effect on MDM2/MDM4 and is 
currently in phase 2 clinical trials for the treatment of T-cell lymphoma (Figure 
2C)(63,64).  Several other intracellular PPIs have been successfully targeted using 
stapled peptides, including the NOTCH transcription factor complex (65), Wnt 
signaling through β-catenin (66), and the PRC2 complex (67).  However, it should be 
noted that only a small subset of stapled peptides are cell permeable and that 
endosomal escape remains a challenge for this class of molecules. 
Cyclic peptide screening and cell permeability 
 mRNA display is an in vitro directed evolution method developed by Roberts 
and Stzosak to screen libraries of randomized peptides for desired properties (e.g. 
binding to a target) by forming a covalent link between each peptide and its 
encoding mRNA (68). This allows functional molecules to be rapidly identified by 
DNA sequencing following selection. As a method, mRNA display has significant 
advantages over older biological display methods such as phage or yeast display 
since the size of the library is not limited by the transformation efficiency of the host 
organism. mRNA display libraries can reach sizes >1015 unique sequences while 
phage display libraries are orders of magnitude smaller (~1011 unique 
sequences)(69).  Post-translational chemical modification of mRNA Display libraries 
can also be carried out without concern for the molecular surface, greatly expanding 
the potential chemical complexity of the library. Compared to ribosome display, 
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mRNA display suffers far 
fewer confounding 
effects from the surface 
on which the peptide is 
displayed (70). Since its 
invention, mRNA display 
has been used to design 
numerous high affinity 
peptides for targets such 
as G-protein coupled 
receptors (8), boxB RNA 
(71), and PDL-1 (72) 
among many others. 
Extensions of the 
technology to evolve 
large macromolecules 
like fibronectin (73) and single-chain antibodies (74) have also been achieved.  
 The process of an mRNA display selection begins with the design of a 
randomized dsDNA library. Libraries can be either totally naïve or a partial 
randomization of an existing sequence and as many as twelve codons can be fully 
randomized (>1015 unique sequences) with complete library coverage before issues 
of translation scale arise. After assembly, the dsDNA library is transcribed to mRNA 
in vitro and ligated to puromycin by a poly-dA linker. Puromycin acts as an 
Figure 3: mRNA Display and SUPR mRNA Display.  A) Diagram of mRNA-
peptide fusion. During translation of the ligated mRNA, puromycin can enter the 
active site of the ribosome to form a covalent amide linkage between the 
peptide and its encoding genetic information. B) SUPR peptide mRNA display 
selection scheme outlining the steps performed in a round of SUPR selection, 




aminoacyl-tRNA mimetic; during in vitro translation of the library it can enter the 
active site of the ribosome and cause the ribosome to stall. Subsequent amide bond 
formation between the primary amine of puromycin and the C-terminus of the 
growing peptide yields a covalent linkage between the translated peptide and its 
encoding mRNA (Figure 3A). The ligated mRNA libraries are translated in vitro 
using rabbit reticulocyte lysate depleted of endogenous mRNA. Following translation 
the mRNA-peptide fusions can be purified from the translation mixture using a poly-
dT resin that associates with the poly-dA linker between the peptide and its 
conjugated mRNA (75). Purified mRNA-peptide fusions are typically reverse 
transcribed to form an mRNA-DNA duplex to stabilize the genetic information and 
prevent inadvertent selection of aptamers. The resulting peptide-DNA-RNA 
conjugates are then screened against an immobilized target protein for binding.   
Following extensive washing to remove non-functional sequences, PCR is 
performed to amplify the genetic information of peptide sequences which bind 
strongly to the target. This yields an enriched library of dsDNA that serves as the 
basis for the next round’s library. From here the process of selection can be 
repeated as many times as necessary for the library to converge (typically 5-7 
rounds) at which point the final pool can be sequenced to identify candidates for 
further investigation. 
 While an eminently powerful tool for identifying peptide sequences that bind 
to target proteins with antibody-like affinities and specificity, the products of mRNA 
display selections suffer from all the traditional liabilities associated with linear 
peptides. Linear peptides are often disordered which impairs binding affinity and 
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imparts susceptibility to enzymatic hydrolysis in the face of serum and intracellular 
proteases.  Linear peptides are almost always non-cell permeable further reducing 
their potential for translation. Scanning Unnatural Protease Resistant (SUPR) 
peptide mRNA display represents an advancement on the original mRNA display 
technology which aims to solve the issues of conformational entropy and protease 
susceptibility (Figure 2B). During SUPR peptide mRNA display selections, amber 
codon nonsense suppression is utilized during in vitro translation to facilitate 
incorporation of a single non-proteogenic amino acid into translated peptides.  While 
any non-proteogenic amino acid may be chosen, N-methylated amino acids such as 
N-methyl-L-alanine or N-methyl-L-norvaline are commonly selected to increase 
resistance to proteases (11). In addition to unnatural amino acid incorporation, 
SUPR peptide mRNA display employs macrocyclization to reduce conformational 
entropy and improve stability. A common method to cyclize peptides involves 
designing the SUPR peptide libraries with a locked C-terminal lysine immediately 
adjacent to the randomized region. Macrocyclization can then be readily achieved 
between the sidechain of lysine and the N-terminus of the peptide using an amine-
reactive crosslinker such as disuccinimidyl glutarate (DSG) using N-
hydroxysuccinimide ester chemistry (8,76). As a final modification of the mRNA 
display selection procedure, SUPR peptide mRNA display selections will typically 
incorporate an additional selection pressure for protease resistance by incubating 
the cyclized mRNA-peptide fusion library with strong protease—such as proteinase-
K—immediately prior to each round of binding selection (Figure 3B). These 
strategies tend to produce hits that not only have high affinity and selectivity for the 
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target protein of interest, but also superb protease stability. Selected peptides are 
frequently observed to incorporate multiple N-methyl amino acids resulting in 
biological half-lives on the order of weeks in human serum (ex vivo)(11). 
While designed to produce serum-stable peptides that bind targets with 
antibody-like affinities, the strategies employed by SUPR peptide mRNA display 
produce peptides that possess many of the features thought to convey cell 
permeability. As we have discussed already, the combination of N-methylation of the 
peptide backbone and cyclization of peptides with a hydrophobic cross-linker has 
been shown to dramatically improve the intrinsic cell permeability of peptides. 
Macrocyclization-promoted formation of intramolecular hydrogen bonding and N-
methylation of the peptide backbone reduce the number of solvent accessible HBDs 
in the peptide backbone which reduces the desolvation penalty the peptide pays to 
associate with the outer surface of the cell membrane, an essential first step to both 
passive diffusion and endocytosis. Hydrocarbon stapling utilizes a hydrophobic 
crosslinker between the sidechains of the i,i+4 residues of peptides to enforce α-
helicity and it has been shown that endosomal uptake and escape efficiencies of 
stapled peptides are dependent on the extent of helix stabilization induced by the 
staple (62). The DSG crosslinker utilized in SUPR mRNA display selections is 
chemically similar to the hydrocarbon bridges in stapled peptides and may convey 
similar properties of improved endosomal uptake by structural stabilization.   
SUPR peptides may be ideal scaffolds for inhibiting intracellular disease-
generating PPIs. The directed evolution technology is highly efficient in generating 
macrocyclic peptides that bind targets with antibody-like affinity, specificity and 
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sufficient surface area to disrupt PPIs while remaining highly resistant to serum 
proteases. SUPR peptide sizes (~1200-2000 Da) are not too large to be 
endocytosed and the combination of macrocyclization and backbone N-methylation 
conveys many of the properties characteristic of peptides that undergo highly 
efficient endosomal uptake and escape into the cytosol.  
SUPR peptide selections for autophagy PPIs 
 Macroautophagy, or simply autophagy, is a catabolic, bulk-degradation 
cellular housekeeping process that may provide an ideal target for the development 
of cell-permeable SUPR peptide PPI inhibitors. Autophagy is mediated by highly 
conserved molecular machinery that typically operates at a low basal level and is 
dramatically upregulated in response to cellular stress such as nutrient deprivation 
(77,78). Upon initiation of autophagy signaling, isolation membranes in the cytosol 
originating from the endoplasmic reticulum are expanded, eventually forming double-
membrane vesicles called autophagosomes. These autophagosomes encapsulate 
portions of the cytosol containing proteins and organelles during their expansion, 
and prior to closure, a number of autophagy adaptor proteins transport damaged or 
superfluous proteins and organelles to the autophagosome interior. The mature, 
closed, autophagosome eventually fuses with the lysosome—forming a vesicle 
called the autolysosome—and hydrolytic lysosomal proteases degrade the contents 
of the vesicle to monomers which are used for downstream metabolism. In this 
manner autophagy lives up to the literal translation of its name: self-eating. Internal 
components of the cell are broken down into basic metabolites to fuel essential 
processes (Figure 4A). 
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As an adaptive stress response, autophagy allows cells to survive transient 
periods of stress. Basal autophagic flux is slow, but can be rapidly upregulated to 
break down nonessential cellular machinery during periods when the cell cannot 
acquire sufficient nutrients from its environment. Like many processes necessary for 
cellular health, autophagy can be co-opted by disease. Many types of cancer—
including ovarian (79,80), breast (81,82), esophageal (83), colon (84), and 
pancreatic (85–87)—constitutively activate autophagy far above basal levels in order 
to survive the nutrient deprived conditions imposed on the developing tumor 
microenvironment by poor and dysregulated vasculature. Additionally, autophagy is 
known to be upregulated in response to internalization of cytotoxic agents or 
extreme internal stress such as can be caused by radiation-induced DNA damage 
and free radical generation. Many cancers will activate autophagy in response to 
chemotherapeutics (83,88–90) and radiation (91–93)—particularly, recurrent, 
metastatic disease that has been treated previously. Because of this, there is 
significant clinical interest in inhibitors of autophagy as an adjuvant to increase or 
restore the effectiveness frontline chemotherapeutics and radiation. Chloroquine and 
hydroxychloroquine have been investigated exhaustively in combination with stand-
of-care cancer therapies. Unfortunately, these compounds don’t specifically target 
autophagy.  Rather, they are non-specific lysosomtropic agents which impair the 
function of lysosomes by raising lysosomal pH and inhibiting the activity of lysosomal 
enzymes. As a consequence, chloroquine and hydroxychloroquine incur 
unacceptably high levels of normal tissue toxicity at therapeutically relevant doses. 
While the toxicity of CQ and HCQ have recently come to the attention of the public 
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as a result of the 
SARS-CoV-2 
epidemic (94), the 
toxic effects of CQ 
and HCQ have long 
been understood. 
Therapeutically 
relevant doses can 





tachycardia (97).  
What is needed are 
inhibitors of the 
autophagy machinery itself. These compounds would block only the PPIs relevant to 
the normal functioning of the autophagic machinery without inducing significant 
toxicity in healthy cells.  
 We hypothesized that SUPR peptides might be the ideal class of compounds 
to inhibit the autophagy machinery in a targeted manner. While the signaling, 
initiation, and maturation of autophagosomes is a complex process that involves 
hundreds of PPIs, one particular family of proteins stands out as a crucial element. 
Figure 4: The autophagy machinery and the role of LC3. A) Diagram of the 
autophagy machinery. Following initiation of autophagy, LC3 is lipidated and 
embedded in the autophagosome surface where it facilitates cargo recruitment and 
closure of the autophagosome. B) LC3 PPIs are mediated by a consensus amino acid 
motif in its binding partners that recognizes two hydrophobic binding pockets on the 
surface of LC3 shown here in red (W-site) and green (L-site).  This hot spot is 
recognized by LC3-interacting motifs (LIMs) which contain the consensus sequence 
W/Y/F-XX-L/V/I.   We hypothesized that SUPR mRNA display could generate cell 





Microtubule-associated protein light-chain 3 (LC3) is a small 14 kDa protein built 
around a ubiquitin core that plays an essential role in the maturation of 
autophagosomes and transport of cargo into their interior. Following translation, LC3 
is acted upon by the autophagy-related protein Atg4 which cleaves the C-terminus of 
LC3 to expose a glycine residue (LC3-I). When autophagy is initiated, LC3-I is 
modified by a series of protein complexes in an E1- and E2-like manner to conjugate 
the membrane lipid phosphatidylethanolamine (PE) to its newly exposed C-terminal 
glycine residue (LC3-II). LC3-II is then embedded in the interior and exterior 
surfaces of the nascent autophagosome membrane where it plays an essential role 
in the expansion and closure of the autophagosome. Additionally, both during and 
following the closure of the autophagosome, LC3 is heavily involved in the 
recruitment of cargo to the autophagosome interior. Many autophagy related cargo 
adapter proteins—such as p62 (SQSTM1), NIX, NBR1, and NDP52—transport 
organelles, proteins, and protein aggregates to the vicinity of the autophagosome 
and then interact with LC3 to transport their cargo to the autophagosome interior 
(98). The vast majority of LC3’s PPIs—including those associated with cargo 
adapter proteins and the protein machinery that post-translationally modifies and 
lipidates LC3—occur via a “hot spot” on the surface of LC3 made up of two 
hydrophobic binding pockets. These two binding pockets recognize a common 
amino acid motif of (W/F/Y)-XX-(L/I/V) where X can represent any amino acid (99–
101). This motif—termed the LC3 interacting motif (LIM)—is found in nearly all of 
LC3’s PPI partners (Figure 4B). 
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The combination of LC3’s essential role in autophagosome maturation and 
the universal nature of the LIM in mediating its function makes the hot spot of LC3 
an appealing target for specific inhibition of autophagy. Small molecules are unlikely 
to be effective at disrupting LC3 hot spot PPIs since it is made up of two pockets 
spaced over a moderate surface area rather a single pocket. Likewise, biologics 
would not be effective inhibitors of LC3 PPIs since the LC3 machinery operates 
exclusively in the cytosol. We hypothesized that SUPR peptide mRNA display might 
represent an ideal technology to develop compounds that possess sufficient size to 
mimic the LIM and disrupt LC3 PPIs while retaining cell permeability and efficient 







DIRECTED EVOLUTION OF CYCLIC PEPTIDES FOR  
INHIBITION OF AUTOPHAGY 
Introduction 
Macroautophagy (hereafter autophagy) is a conserved cellular catabolic 
process responsible for recycling damaged, misfolded, or superfluous cytosolic 
proteins and organelles (77,78,102,103). Upon initiation of autophagy, intracellular 
double membrane vesicles called autophagosomes are formed which engulf and 
sequester organelles, lipids, starches, and proteins (104). Cargo adapter proteins 
(e.g. p62) facilitate the transfer of organelles and protein aggregates to the interior of 
the autophagosome (100,105,106).  Mature autophagosomes then fuse with 
lysosomes to degrade their contents to monomers for downstream anabolism and 
catabolism. Basal autophagy maintains cellular homeostasis through clearance of 
superfluous or damaged proteins and organelles, and autophagic flux is upregulated 
as an adaptive response to nutrient deprivation and exposure to cytotoxic agents. In 
recent years it has become increasingly apparent that autophagy upregulation plays 
a major role in the development and response to treatment of cancer (107–112). 
Many tumors types—including ovarian (79,80,113), pancreatic (85–87,114–116), 
breast (81,82,117), and colon cancers (84)—depend on persistent activation of 
autophagy to sustain growth in the poorly vascularized, hypoxic, and nutrient-
deprived conditions of the tumor microenvironment (118,119). Activation of 
autophagy in response to chemotherapy (83,88–90,113,120,121) and radiation (91–
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93,122–124) has been identified as a major contributing factor to acquisition of 
treatment resistance (108,112,125).  
As a result of its central role in tumor development and treatment resistance, 
there has been intense clinical interest in autophagy inhibitors to augment frontline 
radiation and chemotherapy treatment strategies. As of 2019, over 50 Phase-I and 
Phase-II clinical trials focusing on autophagy inhibitors to treat cancer have been 
with the vast majority combining chloroquine (CQ) or hydroxychloroquine (HCQ) with 
current standard-of-care therapies (126,127). Unfortunately these non-specific 
lysosomotropic compounds inhibit the function of lysosomes in normal tissue leading 
to unwanted toxicities at therapeutically relevant doses (128).  The narrow 
therapeutic window of chloroquine-based drugs argues for the development of 
targeted agents that selectively disrupt the fundamental protein-protein interactions 
(PPIs) of the autophagic machinery. 
Microtubule-associate protein light chain 3 (LC3) is a 14 kDa ubiquitin-like 
protein that is essential to the maturation of the autophagosome, delivery of cargo to 
the autophagosome interior, and fusion with the lysosome. Following translation, 
pro-LC3 is cleaved by Atg4 to expose a C-terminal glycine residue (LC3-I) which is 
uniformly distributed throughout the cytosol. Upon induction of autophagy, LC3-I is 
modified by a series of autophagy-related proteins leading to conjugation of 
phosphatidylethanolamine (PE) to the exposed C-terminus (LC3-II). LC3-II is 
embedded in both inner and outer membranes of the nascent autophagosome 
where it facilitates its elongation and closure.  Membrane-bound LC3-II also interacts 
with autophagy adapter proteins such as p62 (SQSTM1), NIX, NBR1, and NDP52 to 
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transport damaged organelles and protein aggregates to the autophagosome 
interior. Disruption of LC3 processing and embedding—i.e. through LC3 knockout or 
knockout/knockdown of Atg5 or Atg7 which mediate LC3 conjugation to PE—leads 
to dysfunctional phagophore elongation, hampered autophagosome closure, and 
inhibition of fusion between the autophagosome and lysosome (107,129).  
Due to its essential role in the maturation of the autophagosome, blockade of 
LC3 PPIs represents a promising strategy for targeted autophagy inhibition.  The 
vast majority of LC3 PPIs are thought to occur via a “hot spot” on the surface of LC3 
consisting of two hydrophobic binding pockets which recognize a core amino acid 
motif—(W/F/Y)-XX-(L/I/V) where XX can be any amino acids (99,100,130).  This 
sequence is referred to as the LC3-interacting motif (LIM) and is found in nearly all 
proteins that interact with LC3.  
Inhibiting PPIs with small molecules remains challenging due to their small 
size and molecular radius (131,132).  Small, linear peptides, which have shown 
great promise as PPI disruptors in vitro, cannot readily cross biological membranes 
and suffer from poor serum stability.  LC3-binding peptides derived from naturally 
occurring LIMs possess relatively low affinities (mid to low micromolar range) and 
would likely suffer from the same stability and permeability issues that typically limit 
the usefulness of small, linear peptides in vivo (133).   
In natural product space, there are numerous examples of cyclic peptides that 
readily cross the cell membrane (e.g. Microsytin LR, α-amnitin, and phalloidin (134–
136)), exhibit nanomolar potencies against intracellular targets, and show sufficient 
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biostability for in vivo applications (137,138).  Consequently, macrocyclic peptide 
scaffolds have received a great deal of attention as a means to generate PPI-
disrupting compounds with drug-like affinity, stability, and cell permeability (15).   
One strategy for designing cell-permeable cyclic peptides focuses heavily on N-
methylation of amino acids within the context of macrocyclic scaffolds.  The work of 
Lokey and co-workers, for example, has shown that extensive methylation of 
backbone amides within the peptide macrocycle effectively eliminates hydrogen 
bonds between backbone amide protons and water and results in significant 
enhancement of passive cell permeability (139,140).  Pei and co-workers have 
elegantly demonstrated that cyclic, amphipathic cell-penetrating peptides can drive 
the uptake of otherwise non-permeable peptide and protein cargo.  These cyclic 
sequences can be incorporated within the context of bioactive macrocycles to 
greatly enhance cell uptake with minimal perturbation of biological function (141). 
The use of “stapled” peptides represents a third approach to enhancing cell uptake 
(61).  In this approach, ring-closing metastasis is employed to cross-link the side 
chains of α-helical peptides, providing conformational constraint and stabilizing i+4 
and i, i+7 hydrogen bonding patterns (61).  This approach has been used to design 
proteolytically stable, cell permeable peptides that target MDM2/4 and inhibit 
proteasome-mediated degradation of p53 (142).   
Scanning Unnatural Protease Resistant (SUPR) mRNA display provides a 
method to rapidly evolve macrocyclic, protease-resistant peptides for in vivo 
applications (143,144).  SUPR peptide mRNA Display is a recent advancement of 
mRNA display (6,69) that integrates disuccinimidyl glutarate-based macrocyclization, 
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incorporation of non-proteogenic N-methyl amino acids, and pre-screening for 
protease resistance (76,145). This technique leads to the selection of macrocyclic 
peptides with high target affinity and dramatically enhanced stability to hydrolytic 
degradation. The SUPR peptide scaffold also recapitulates many of the 
physiochemcial properties of cell permeable macrocyclic peptides (backbone amide 
N-methylation and a hydrophobic crosslinker) suggesting that SUPR peptide may 
possess the requisite cell permeability for disruption of intracellular PPIs.   
We carried out SUPR mRNA display selections against recombinant LC3 to 
identify LC3-binding SUPR peptides with sufficient affinity, stability, and cell 
permeability for in vivo applications. The most promising candidate from the 
selection (SUPR4B1W) binds to LC3A and LC3B with mid-nanomolar affinity and 
was significantly more stable to proteolytic degradation than its linear and non-
methylated counterparts. SUPR4B1W sensitized multiple cancer cell lines to 
cisplatin treatment, resulted in accumulation of intracellular p62, and significantly 
modulated the LC3-I/LC3-II ratio in cell culture.  Finally, SUPR4B1W, in combination 
with carboplatin, effectively prevented intraperitoneal tumor outgrowth in orthotopic 
mouse models of ovarian cancer after four weeks of treatment.  
Materials & Methods 
Cell Lines 
OVCAR5, OVCAR8, and HEY cell lines were maintained in RPMI 1640 
medium supplemented with 10% fetal bovine serum, 2 mM L-Glutamine, 1 mM Na-
Pyruvate, and 1% (v/v) penicillin-streptomycin. SKOV3 cells were maintained in in 
McCoy’s 5A medium supplemented with 10% fetal bovine serum, 2 mM L-
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Glutamine, and 1% (v/v) penicillin-streptomycin. MDA-MB-231, PANC-1, and MIA 
PaCa-2 cell lines were maintained in DMEM medium supplemented with 10% fetal 
bovine serum and 1% (v/v) penicillin-streptomycin. 
HeLa cells were maintained in RPMI 1640 supplemented with 5% fetal bovine 
serum. HeLa cells stably expressing EGFP-LC3B were generated using pEGFP-LC3 
(Addgene #24920). HeLa cells were directly transfected with pEGFP-LC3 using 
Mirus TransIT-LT1 transfection reagent and then maintained in RPMI 1640 
supplemented with 5% fetal bovine serum and 400 µg/mL active G418 for 14 days. 
Single-cell sorting was performed on a FACSAria IIIu instrument. HeLA-GFP-LC3B 
cell lines derived from single cells were maintained in RPMI 1640 supplemented with 
5% fetal bovine serum and 200 µg/mL active G418. 
Expression and Purification of Recombinant LC3 
pQTEV-MAP1LC3A vectors for expression and purification of N-terminally 
polyhistidine tagged recombinant LC3A were ordered through Addgene (Plasmid 
#34824) and transformed into BL21-DE3 pLysS E. coli (Promega). 2 Liters of LB 
media were inoculated from overnight cultures and grown to an OD600 of 0.6 before 
expression was induced with IPTG at a concentration of 0.6 mM for 3 hours. Cell 
pellets were resuspended in 15 mL equilibration buffer (20 mM HEPES pH 7.2, 200 
mM NaCl, 10 mM imidazole) and lysed by sonication. Clarified lysate was incubated 
with 1 mL Ni-NTA resin for one hour, loaded onto a fritted column, and flow-through 
eluted. Resin was washed four times with equilibration buffer and the protein was 
eluted with 15 mL elution buffer (20 mM HEPES pH 7.2, 200 mM NaCl, 250 mM 
imidazole). Eluted protein was buffer exchanged against dialysis buffer (20 mM 
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HEPES pH 7.2, 200 mM NaCl, 25% glycerol) using 3,000 MWCO dialysis tubing 
(Fisher) and concentrated by Amicon Ultracel 3k centrifugal filters (Millipore) to a 
final concentration of 1.4 mg/mL (7 mg/L total yield). His6-LC3A was biotinylated 
using 5x molar excess biotin-NHS (Sigma).  The reaction was incubated on ice for 2 
hours before excess biotin-NHS was removed by 7,000 MWCO Zeba spin column 
(Thermo). Biotinylation was confirmed by HABA-Avidin assay (Pierce) and final 
concentration of biotinylated His6-LC3A was measured at 1.25 mg/mL by BCA 
assay.   
pDEST15-LC3A and pDEST15-LC3B constructs for N-terminally tagged GST-
LC3A and GST-LC3B were provided by Dr. Terje Johansen1,2. Transformation and 
expression of plasmids were performed as described above. Clarified lysate was 
incubated with 1 mL glutathione agarose (Goldbio) for one hour, loaded onto a fritted 
column, and flow-through eluted. Resin was washed four times with equilibration 
buffer and the protein was eluted with 15 mL elution buffer (20 mM HEPES pH 8.0, 
200 mM NaCl, 10 mM reduced glutathione). Eluted protein was exchanged against 
dialysis buffer (20 mM HEPES pH 7.2, 200 mM NaCl, 25% glycerol) using 3,000 
MWCO dialysis tubing (Fisher) and concentrated by Amicon Ultracel 3k centrifugal 
filters (Millipore) to a final concentration of 1.18 mg/mL GST-LC3A and 1.13 mg/mL 
GST-LC3B by BCA assay. 
Synthesis of N-methyl Alanine amber codon suppressor 
NVOC-N-methyl-L-alanine cyanomethyl ester was synthesized according to 
previously described protocols for conjugation to the dinucleotide pdCpA and ligation 
to the amber suppressor THG73 tRNA.  NVOC-Cl (269 mg, 970 µmol, Sigma) was 
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dissolved in 8 mL THF and added dropwise to N-methyl-L-alanine (100 mg, 969.7 
µmol, Sigma) dissolved in 2 mL sodium carbonate.  10 N NaOH was added to bring 
the reaction mixture to pH > 10 and the reaction mixture was stirred at room 
temperature protected from light for 3 hours. Solvents were removed in vacuo and 
the dried compound was dissolved in 3 mL dry DMF to which 2 mL chloroacetonitrile 
and 600 µL triethylamine were added. The reaction was stirred under nitrogen 
overnight before the solvents were removed in vacuo and the remaining solid was 
purified by silica gel flash chromatography. 
NVOC-N-methyl-L-alanine cyanomethyl ester (12.7 mg, 33.2 µmol) and 
pdCpA (5 mg, 8.3 µmol, TriLink Biotechnologies) were dissolved in 400 µL dry DMF 
under nitrogen and stirred at room temperature protected from light for 4 hours 
before quenching the reaction with 20 µL ammonium acetate (25 mM, pH 4.5). The 
crude product was purified by reverse phase preparative HPLC using a gradient of 
ammonium acetate (25 mM, pH 4.5) to acetonitrile and the fractions corresponding 
to the product were combined and lyophilized yielding 3 mg of NVOC-N-Methyl-L-
Alanine-pdCpA (36.1% yield).  Product was confirmed by observing the [M+H]+ peak 
at MW = 961.54  (expected 960.21) using electrospray ionization mass 
spectrometry. 
pUC19-THG73tRNA plasmid (a gift from Dennis Dougherty, California 
Institute of Technology) containing the gene for THG73 amber codon suppressor 
tRNA was PCR amplified and linearized by overnight FokI digestion at 37C. THG73 
tRNA was transcribed in vitro by T7 RNA polymerase, purified by Urea-PAGE and 
dissolved in water (2 µg/µL final concentration).  
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NVOC-N-methyl-L-alanine-pdCpA was ligated to THG73 tRNA just prior to its 
use in in vitro translation reactions. THG73 tRNA (20 µg in 10 µL water) and HEPES 
(20 µL, 10 mM, pH 7.5) were combined and heated at 95 °C for 3 minutes, then 
cooled to 37 °C.  NVOC-N-Methyl-L-Alanine-pdCpA (8 µL, 3 mM in DMSO) was 
added to the tRNA-HEPES mixture along with water (30 µL), T4 RNA Ligase (4 µL, 
New England Biolabs), and 10x T4 Reaction Buffer (8 µL, New England Biolabs).  
The reaction was incubated at 37 °C for 65 minutes, extracted with 25:24:1 
phenol:chloroform:isoamyl alcohol (Sigma), and precipitated with >3 volumes cold 
ethanol at -80 °C. The precipitate was dried by vacuum, dissolved in 20 µL 1 mM 
sodium acetate, quantified by measuring A260, and adjusted to a final concentration 
of 1 µg/µL.  Immediately prior to in vitro translation the AA-tRNA solution was 
deprotected by short-wave UV for 15 minutes. 
SUPR mRNA Display Library Preparation 
To perform selections, we assembled a DNA library encoding eight random 
positions between an N-terminal methionine residue and a C-terminal lysine residue. 
The library was constructed by the PCR amplification of the antisense template oligo 
(5’ TCC GCT GCC GGA TTT SNN SNN SNN SNN SNN SNN SNN SNN CAT TGT 
AAT TGT AAA TAT AAT T 3’ where N= A, C, G or T and S = C or G) with the 
primers MKForward (5’ TAA TAC GAC TCA CTA TAG GGA CAA TTA CTA TTT 
ACA ATT ACA 3’) and MKReverse (5’ GCC AGA TCC GCT GCC GGA TTT 3’). In 
addition to the open reading frame, the DNA library contains a T7 promoter 
sequence and a ribosome binding site. 
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The mRNA display library was generated by in vitro transcription of the DNA 
library. Transcription was performed by incubating DNA libraries with transcription 
buffer (80 mM HEPES-KOH, pH 7.5, 2 mM spermidine, 40 mM DTT, and 25 mM 
MgCl2) and rNTP mixture (4 mM ATP, GTP, CTP, UTP) at 65 °C for 15 minutes 
before cooling briefly at room temp and adding T7 RNA polymerase. Transcription 
reactions were allowed to proceed overnight at 37 °C and were terminated by phenol 
chloroform extraction and ethanol precipitation. The mRNA library was then purified 
by running denaturing Urea-PAGE, cutting out mRNA bands, and recovering by 
electroelution. 
The mRNA library was then ligated at the 3’ end to a puromycin-DNA linker 
(pF30P - 5' 8AA AAA AAA AAA AAA AAA AAA A77 7AC C6 3') where 6 = 
puromycin CPG, 7 = spacer phosphoramidite 9, 8 = phosphate). Puromycin acts as 
an aminoacyl tRNA mimetic that can enter the active site of the ribosome to form a 
covalent link between the translated peptide and its encoding mRNA resulting in an 
mRNA-peptide fusion. Ligation reactions were performed by incubating 3000 pmol of 
mRNA library with 1.2 molar excess PF30P, 1.4 molar excess splint oligo (5’ TTT 
TTT TTT TTT TGC CAG ATC CGC TG 3’), and T4 DNA ligase at room temperature 
for 75 minutes. The ligated mRNA library was then purified by Urea-PAGE and 
electroelution as described above. 
mRNA Display Selection 
In vitro translations were performed using rabbit reticulocyte lysate kits 
(Ambion). To assemble the translation reaction 10 pmol ligated mRNA library was 
added to rabbit reticulocyte lysate (17 µL), EasyTag [35S]-Methionine (3 µL, 8 
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µCi/µL, PerkinElmer), amber suppressor tRNA charged with N-Methyl Alanine (2.25 
µL, 1 µg/µL), 20x high salt mix (1.25 µL, KOAc 3 M, MgOAc 10 mM, creatine 
phosphate 200 mM, and 1 mM of each amino acid except methionine). After a 70 
minute incubation at 30 °C the translation mix was supplemented with 100 mM KCl 
and 0.5 mM MgCl2 to promote the formation of mRNA-peptide fusions. mRNA-
peptide fusions were purified from the translation mix using oligo-dTcellulose (GE) 
which selectively binds to the poly dA linker between the mRNA template and 
puromycin. Oligo dT cellulose was washed with dT binding buffer (Tris-HCL pH 8.0 
20 mM, NaCl 1 M, EDTA 1 mM, Triton-X 0.2% (v/v)) and translation mixes were 
rotated with 10 mg of oligo dT cellulose in 500 µL dT binding buffer at 4 °C for 60 
minutes. The oligo-dT cellulose was then washed with dT wash buffer (Tris-HCL pH 
8.0 20 mM, 300 mM NaCl) and mRNA–peptide fusions were eluted in 60 °C water.  
Following dT purification, mRNA-peptide fusions were ethanol precipitated 
and resuspended in 50 mM phosphate buffer pH 8.0 for cyclization between the 
primary amine of the lysine side chain and at the N-terminal amine using the 
crosslinker disuccinimidyl glutarate (DSG). The cyclization reaction was carried out 
by adding DSG to the mRNA-peptide fusions to a final concentration of 200 µg/mL 
and rotating at room temperature for 60 minutes. Cyclized mRNA-peptide fusions 
were then dT purified using the method described above. Following purification, 
mRNA-peptide fusions were reverse transcribed by M-MulV reverse transcriptase 
(NEB). Reverse transcribed fusions were subjected to protease screening by 
incubating with proteinase-K agarose (Sigma) for 30 s before filtering with Spin-X 
microcentrifuge column. To eliminate sequences with significant off-target binding to 
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the resin, proteinase-treated fusions were incubated with streptavidin-agarose (Life 
Technologies) at 4 °C for 60 minutes before recovering unbound fusions using Spin-
X microcentrifuge column.  
Selection targets were prepared by incubating streptavidin-agarose with 1.5x 
molar excess biotinylated-LC3A at 4 °C with rotation for 30 minutes to saturate the 
resin with target. The immobilized target was then washed thoroughly with selection 
buffer (20 mM HEPES-KOH pH 7.5, 150 mM NaCl, 0.2% (v/v) Tween-20, 1 mg/mL 
BSA, 50 µg/mL tRNA, 1 mM β-mercaptoethanol). Selections were carried out by 
incubating fusions with immobilized target with rotation for 2 hours. Selection 
incubations were carried out at 4 °C for the first four rounds of selection and then 
split into parallel selections carried out at 25 °C or 4 °C thereafter. Following 
incubation, the selection resin was washed 3 times with selection buffer and filtered 
with a Spin-X column. The resin was then washed two additional times in selection 
buffer without BSA or tRNA and bound fusions were eluted in 0.15% sodium dodecyl 
sulfate (SDS) (Thermo-Fisher). SDS was subsequently precipitated using SDS-Out 
(Thermo-Fisher) and eluted fusions were filtered and ethanol precipitated. The 
precipitated pellet was resuspended in dH2O and one fifth of the total volume was 
subjected to PCR amplification using the MKFor and MKRev primers. Small volumes 
of PCR product were removed every 3 PCR cycles and tested by 4% agarose gel to 
identify formation of the amplified product. The remaining eluted fusions were 
amplified using the minimum PCR cycles as defined in the previous step. Further 
selection rounds were conducted using previous round’s enriched dsDNA library. 
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The library was considered converged when the number of PCR cycles required to 
recover the enriched dsDNA library did not decrease in three consecutive rounds. 
Sanger Sequencing 
After libraries converged, the final pool was TOPO-TA cloned into pCR™II-
TOPO® vector (Thermo-Fisher), transformed into One Shot TOP10 chemically 
competent E. coli (Thermo-Fisher), and plated on ampicillin-agarose to isolate 
individual sequences from the final selection pool. Twelve colonies from each 
parallel selection were selected at random and plasmid minipreps (Life 
Technologies) were prepared from 5 mL overnight cultures. Amplified plasmids were 
submitted for Sanger sequencing and analyzed using FinchTV software. Peptide 
Synthesis and Cyclization 
Peptide Synthesis and Cyclization 
Peptides were synthesized using a Prelude automated peptide synthesis 
instrument (Protein Technology, Inc.). 2-chlorotrityl resin (0.439 g, 0.5 mmol, 
Advanced Chemtech) was swollen in DMF for 1 hour and washed twice with 5 mL 
DMF. The initial C-terminal amino acid coupling to the resin was performed manually 
prior to automated synthesis of peptides. 2 equivalents Fmoc-propargylglycine (1 
mmol, 335 mg) and 3 equivalents N,N-diisopropylethylamine (DIEA, 1.5 mmol, 262 
µL, Sigma) were added to the swelled resin in 6 mL DMF and rotated at room 
temperature  for 1 hour.  To synthesize each peptide, 100 mg of Fmoc-
propargylglycine resin was loaded onto the automated synthesis instrument and 
synthesis was performed with 3 equivalents of Fmoc amino acid (Oakwood 
Products, Inc.), DIEA, and N,N,N′,N′-Tetramethyl-O-(1H-benzotriazol-1-yl)uronium 
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hexafluorophosphate (HBTU, Oakwood Products, Inc.) in N-methyl Pyrrolidone 
(NMP). A total of 3 coupling reactions (10 minute duration) were performed for each 
amino acid building block.  Deprotection of Fmoc groups was achieved using 20% 
(v/v) piperidine in NMP. After synthesis and final deprotection, resin was washed 5x 
with NMP (1.5 mL, 2.5 minutes), 5x with DCM (1.5 mL, 2.5 minutes), and dried 
under vacuum for 1 hour. Peptides were cleaved from the resin with 95% (v/v) 
trifluoroacetic acid, 2.5% (v/v) water, 2.5% (v/v) triisopropylsilane at room 
temperature for 3 hours, precipitated with cold diethyl ether, and dried under 
vacuum. Crude products were purified by reverse phase preparative HPLC (Luna 
Phenomenex, 5 µm C18(2), 250 mm x 21.2 mm LC column) using gradient elution 
(5-95% Buffer B over 45 minutes; Buffer A dH2O + 0.1% (v/v) TFA, Buffer B CH3CN 
+ 0.1% (v/v) TFA). Appropriate fractions were combined and lyophilized yielding a 
white solid. Purified products were confirmed by electrospray ionization mass 
spectrometry.  
Amine reactive cross-linker chemistry was utilized to cyclize peptides 
between the N-terminus of the peptide and the side-chain of a C-terminal lysine 
residue. Purified linear peptide was dissolved in DMF and mixed with 1.1 equivalents 
of disuccinimidyl glutarate (DSG) and 7 equivalents DIEA at room temperature for 3 
hours. After 3 hours the reaction was quenched with hydroxylamine (10 mM final 
concentration) for 15 minutes and solvent was removed in vacuo. The crude product 
was dissolved in 1 mL 95:5 (v/v) dH2O:CH3CN + 0.1% (v/v) TFA and purified by 
reverse phase preparative HPLC using gradient elution (5-20% Buffer B over 5 
minutes, 20-95% Buffer B over 60 minutes; Buffer A dH2O + 0.1% (v/v) TFA, Buffer 
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B CH3CN + 0.1% (v/v) TFA). Appropriate fractions were combined and lyophilized 
yielding a white solid. Purified products were confirmed by electrospray ionization 
mass spectrometry.  
Fluorophore Conjugation of SUPR Peptides 
Copper-catalyzed click chemistry was used to conjugate fluorescein-azide to 
the side-chain alkyne of the C-terminal propargylglycine residue in SUPR peptides. 
Between 2-3 µmol of each peptide was dissolved in DMSO and added to 1.2 
equivalents FAM-azide, 6-isomer (50 mg/mL, Lumiprobe), 50 µL click solution (16 
mg/mL CuSO4·2H2O and 30 mg/mL L-ascorbic acid in dH2O), 5 µL of tris-
(benzyltriazolylmethyl)amine (TBTA, 100 mg/mL in DMF). Reaction mixture was 
brought to a final volume of 150 µL with dH2O and rotated at room temperature for 2 
hours and purified by reverse phase preparative HPLC (Luna Phenomenex, 5 µm 
C18(2), 250 mm x 21.2 mm LC column) using gradient elution (5-95% Buffer B over 
45 minutes; Buffer A dH2O + 0.1% (v/v) TFA, Buffer B CH3CN + 0.1% (v/v) TFA). 
Appropriate fractions were combined and lyophilized yielding a yellow-green solid. 
Purified products were confirmed by electrospray ionization mass spectrometry.  
Copper-catalyzed click chemistry was used to conjugate carboxy-X-
rhodamine (ROX) azide to the side-chain alkyne of the C-terminal propargylglycine 
residue of SUPR4B1W. 3 µmol of SUPR4B1W was dissolved in DMSO and added 
to 1.2 eq ROX-azide (50 mg/mL, Lumiprobe), 50 µL click solution (16 mg/mL 
CuSO4·2H2O and 30 mg/mL L-ascorbic acid in dH2O), 5 µL of TBTA (100 mg/mL). 
Reaction mixture was brought to a final volume of 150 µL with dH2O and rotated at 
room temperature for 2 hours and purified by reverse phase preparative HPLC 
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(Luna Phenomenex, 5 µm C18(2), 250 mm x 21.2 mm LC column) using gradient 
elution (5-95% Buffer B over 45 minutes; Buffer A dH2O + 0.1% (v/v) TFA, Buffer B 
CH3CN + 0.1% (v/v) TFA). Appropriate fractions were combined and lyophilized 
yielding a light purple solid. Purified products were confirmed by electrospray 
ionization mass spectrometry 
Biotin Conjugation of SUPR peptides 
Copper-catalyzed click chemistry was used to conjugate biotin-azide to the 
side-chain alkyne of the C-terminal propargylglycine residue in SUPR peptides. 2 
µmol of SUPR4B1W was dissolved in DMSO and added to 1.2 equivalents Biotin-
PEG3-azide (Thermo-Fisher), 50 µL click solution (16 mg/mL CuSO4·2H2O and 30 
mg/mL L-ascorbic acid in dH2O), 5 µL of tris-(benzyltriazolylmethyl)amine (TBTA, 
100 mg/mL). Reaction mixture was brought to a final volume of 150 µL with dH2O 
and rotated at room temperature for 2 hours and purified by reverse phase 
preparative HPLC (Luna Phenomenex, 5 µm C18(2), 250 mm x 21.2 mm LC 
column) using gradient elution (5-95% Buffer B over 45 minutes; Buffer A dH2O + 
0.1% (v/v) TFA, Buffer B CH3CN + 0.1% (v/v) TFA). Appropriate fractions were 
combined and lyophilized yielding a white solid. Purified products were confirmed by 
electrospray ionization mass spectrometry.  
Radiolabeled Binding Assays 
Plasmid minipreps for individual clones were PCR amplified using the MKFor 
and MKRev primers to obtain dsDNA for individual sequences from the final pool. 
These dsDNA sequences were transcribed, ligated, and translated in the presence 
of [35S]-Methionine as described above. Following incubation for 70 minutes, RNAse 
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A (1 µL, 10 mg/mL, MilliporeSigma) was added to the translation mix to digest the 
mRNA fused to the peptides which might impact binding. The peptides were purified 
from translation using dT cellulose and subjected to cyclization as described above. 
A small portion of the cyclized and purified translation product was reserved for 
scintillation counting and the remaining product was incubated with biotinylated-
LC3A immobilized on neutravidin-acrylamide (Thermo-Fisher) at 25 °C with rotation 
for 1 hour. The incubation mix was pelleted, the supernatant reserved, and the 
pelleted resin washed three times with Spin-X microcentrifuge columns. The resin 
pellet and portions of the supernatant and each wash were subjected to scintillation 
counting and a percentage of input activity that remained bound to the immobilized 
target after washing was calculated for each clone. 
Fluorescence Polarization Assays 
For fluorescence polarization assays, stock solutions of GST, GST-LC3A and 
GST-LC3B were adjusted to 5 µM and serially diluted to concentrations between 5 
µM and 2.4 nM in triplicate in black polystyrene 96-well plates (Corning). FAM-
labeled peptide was added to each well to a final concentration of 10 nM and 
incubated at room temperature for 2 hours. Fluorescence polarization was measured 
on a Biotek Synergy Neo Microplate Reader using a dual PMT FP 485/528 filter set. 
The mean value of polarization was calculated for each sample concentration and 
mean polarization values for GST were subtracted from GST-LC3 measurements to 
eliminate any effects from non-specific interactions. Mean fluorescence polarization 
measurements were converted to fluorescence anisotropy and fit to a one-site 
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saturation binding model in Graphpad Prism 8 to calculate equilibrium binding 
constants for each peptide. 
Atg4B Activity Assay 
LC3-AMC (R&D Systems) was diluted in Reaction Buffer (25 mM Tris, 150 mM 
NaCl, 10 mM DTT) to a final concentration of 230 nM.  20 µL of LC3-AMC was 
added to 5 µL SUPR peptide (1 µM, 500 µM, 250 µM, 0 µM in Reaction Buffer) in a 
96-well microtiter plate pre-blocked with 5 mg/mL BSA.  After incubating for 5 
minutes at room temperature, 25 µL 400 pM Atg4B (R&D Systems) was added to 
initiate the reaction.  The final concentrations of each component in the hydrolysis 
reaction were LC3-AMC (92 nM), Atg4B (200 pM), and SUPR peptide (0-100 µM), 
and the final volume was 50 µL.  The hydrolysis reaction was allowed to progress at 
room temperature for 40 minutes and the fluorescence measured each minute (λEX 
= 380 nm, λEM = 460 nm) on a BioTek Synergy H4 microplate reader.  The resulting 
fluorescence at each time point (AU) was normalized to the fluorescence at t=0 to 
compute the normalized product.  Each reaction condition was carried out in 
triplicate and the values shown represent the mean value of three measurements.   
Proteinase-K Stability Assays 
Protease stability was assessed by treating peptide solutions (1 mM in PBS, 
final volume 500 µl) with 0.3 mg proteinase-K agarose (Sigma). At time intervals of 
0, 30, 60, 120, and 240 minutes, 50 µL samples were taken from the digestion 
mixture and separated from proteinase-K agarose by centrifugal filtration with Spin-X 
columns. Samples were then subjected to analytical HPLC (Agilent  1100  Series  
HPLC  equipped  with  a  Phenomenex  Gemini  5µ  C18 110A  column) using 
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gradient elution (10-30% Buffer B over 30 minutes; Buffer A dH2O + 0.1% (v/v) TFA, 
Buffer B CH3CN + 0.1% (v/v) TFA). Peak area was calculated for the peak 
corresponding to the intact peptide for each sample and the fraction intact was 
calculated for each time point. Half-lives for each peptide were calculated in 
Graphpad Prism 8.  
ATG8 homologue Selectivity 
SUPR-4B1W-biotin was conjugated to neutravidin acrylamide by adding 2 µL, 
1 mM SUPR-4B1W-biotin to 50 µL neutravidin acrylamide slurry (Thermo-Fisher) 
with 200 µL binding buffer (150 mM NaCl, 50 mM Tris-HCl, pH 7.8) and rotating for 1 
hr at room temperature. The immobilized peptide resin was then washed twice with 
200 µL binding buffer using Spin-X centrifugal filter columns.  
pET151/D-TOPO bacterial expression vectors containing the genes for LC3A, 
LC3B, LC3C GABARAPL1, GABARAPL2, ATG8, and ubiquitin were designed and 
ordered from Thermo-Fisher. Forward and Reverse primers were designed to allow 
PCR amplification of each gene from the bacterial vectors with the addition of 5’ T7 
promotor and ribosome binding site sequences. Following PCR amplification, DNA 
templates were extracted with 25:24:1 Phenol:chloroform:isoamyl alcohol (Sigma) 
and precipitated with >3 volumes cold ethanol at -80 °C. The centrifuged precipitate 
was dried by vacuum and resuspended in 100 µL dH2O. DNA templates were 
transcribed in vitro by T7 RNA polymerase and purified by UreaPAGE. 10 pmol of 
each RNA template were translated in vitro in the presence of [35S]-Methionine as 
described previously.  
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To test selectivity of SUPR4B1W for the various ATG8 homologues, 8 µL of 
translation reaction was added to 10 µL of either peptide-saturated resin (125 
pmol/µL resin) or naked resin in triplicate and brought to a final volume of 50 µL with 
binding buffer (20 mM HEPES-KOH pH 7.5, 150 mM NaCl). Reaction mixtures were 
rotated at room temperature for 60 minutes before reaction mix was transferred to a 
Spin-X column, washed 3x with 200 µL binding buffer, and washed resin was 
subjected to scintillation counting.  
Fluorescence microscopy 
HeLa cells stably expressing eGFP-LC3 were seeded at a density of 30,000 
cells/well in an 8-well chambered coverslide (Corning) 24 hours before beginning 
treatment. Cells were treated with complete media supplemented with 500 nM 
SUPR4B1W-ROX for 12 hours. After 12 hours cells were either starved with Hank’s 
Balanced Salt Solution (Corning) or were given fresh complete media for 2 hours 
and then subjected to live-cell fluorescence confocal imaging.   
Quantification of colocalization between SUPR4B1W-ROX and eGFP-LC3 
puncta was performed in ImageJ. Three fields of images for both starved and 
unstarved treatments were selected and split into red and green channels. Cells that 
were mitotic or had lost eGFP-LC3 expression were removed from the analysis. 
Manders M1 and M2 coefficients were calculated using the Just Another 
Colocalization (JACoP) plugin using appropriate pixel intensity thresholding to filter 
background signal.  
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Cellular Cisplatin Sensitization Assays 
OVCAR8, OVCAR5, HEY, SKOv3, MDA-MB-231, PANC-1, and MIA PaCa-2 
cells were seeded in black-walled 96-well plates at a density of 5,000 cells/well 24 
hours prior to treatment. Cells were treated with SUPR peptides (50 µM) or 
chloroquine (5 µM, Sigma) both in the presence and absence of cisplatin (10 µM, 
Sigma) in order to determine the effect of autophagy inhibition on cellular viability in 
treatment resistant cell lines. Cells were treated for a total of 48 hours (n = 6 per 
treatment group) prior to viability testing by 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) assay. Differences in cellular viability 
measurements between treatment groups were evaluated in R by applying two-way 
ANOVA after applying a log10 or square root transformation to satisfy normality. 
Cisplatin Sensitization Animal Model 
Athymic nude mice were injected with 2 million OVCAR8 cells IP. Mice were 
treated with SUPR4B1W (10 mg/kg) combined with carboplatin (25 mg/kg) or saline 
3x per week by IP injection. Each treatment group had 8 mice, with the exception of 
the group treated with carboplatin alone which had 4 mice. Treatments were 
administered for 3 weeks before mice were sacrificed and tumors were dissected 
and weighed. Differences in tumor mass between treatment groups were evaluated 
in R by a nonparametric Mann-Whitney-Wilcoxon rank-sum test. 
The assay was repeated with the additional treatment groups for 
combinations of scrambled SUPR4B1W (10 mg/kg) with carboplatin (25 mg/kg) or 
saline. Treatment group size was expanded to 10 mice and the duration of the 




To determine the independent and interactive effects of cisplatin and 
SUPR4B1W on cell viability, we used a two-way ANOVA with Type I sum of squares 
on A600 absorbance. Log10 and square root transformations were used on OVCAR8 
and HEY cell line absorbance data, respectively, to achieve satisfactory normality. 
To determine the independent and interactive effects of carboplatin and SUPR4B1W 
structure on tumor weight in mice, we used a two-way ANOVA with Type III sum of 
squares. A square root transformation was necessary to handle right skewedness in 
Week 4 data. Following both analyses, Tukey’s HSD via the package lsmeans was 
used to determine which treatment means were significantly different from one 
another. 
Results & Discussion 
Our goal was to generate small, protease-stable peptides with high affinity 
and selectivity for LC3. In order to generate target for selection, His6-tagged LC3A 
was expressed in E. coli and purified by Ni-NTA affinity chromatography (8.1 mg/L 
culture). Biotinylation of recombinant LC3A was carried out using Biotin-NHS and 
confirmed by HABA-Avidin assay.  LC3A-biotin was then immobilized on streptavidin 
agarose for selection.  
Selection against LC3A using MK8 Library 
Selections against LC3A were carried out using SUPR peptide mRNA 
display(144). The DNA template library was designed with eight random codons and 
a fixed lysine codon to allow cyclization between the side chain of lysine and the N-
terminal amino group (Figure 1A).  The resulting library was translated in the 
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LC3A, binding of 




evidenced by a 
reduction in the 
number of PCR 
cycles required to 
amplify the 
enriched library 
(Figure 1B). Sequencing revealed three dominant sequence families in the final pool 
which each share a consensus motif (Y/F/N/L)-XXX-(L/V/I) analogous to canonical 
LIM albeit with an additional amino acid in the spacer region (Figure 1C). It is 
possible that this additional amino acid arose from the more constrained 
conformation of the cyclic peptide compared to the linear LIMs found in LC3 adaptor 
proteins which typically occur as elongated β-strands(101).  
Figure 1  Selection of LC3-binding SUPR peptides.  A) Schematic of the MX8K 
library.  Eight randomized codons were installed between the N-terminal methionine 
and a locked lysine residue.  The library was cyclized by disuccinimidyl glutartate 
(DSG)-mediated crosslinking of the N-terminal amino group and the side-chain 
amino group of lysine. B) After seven rounds of selection the number of PCR cycles 
required to amplify the enriched dsDNA library declined and plateaued indicating 
convergence of the library. C) Sequencing of the final pool revealed three dominant 
peptide families (purple, blue and red).  >80% of sequences identified had 
incorporated an N-methyl-L-alanine residue (Z) in the final random position of the 
macrocycle. D) Each sequence was synthesized as an mRNA-peptide fusion and 
panned against LC3A immobilized on streptavidin acrylamide or streptavidin 
acrylamide alone (resin).  Clone 4B showed 86% binding to immobilized LC3 and 




 Sequencing data also revealed that >80% of the clones analyzed from the 
round 7 pool incorporated N-methyl-L-alanine at position 9 within the macrocycle 
indicating that the selection provides a significant selection pressure for N-methyl-L-
alanine incorporation at this position. In order to identify the highest affinity clones 
from the round 7 pool, we performed radioligand binding assays. Individual clones 
were translated as mRNA-peptide fusions in the presence of [35S]-methionine, 
cyclized, and treated with RNAse A to remove the RNA portion yielding peptides 
conjugated only to the poly-dA linker. Radiolabeled peptide-DNA conjugates were 
then panned against LC3A immobilized on neutravidin-acrylamide or resin alone. 
After an hour incubation at room temperature the resins were washed thoroughly 
and analyzed by scintillation counting. While several clones showed a moderate 
level of target-specific binding, clone 4B (cycl MFPHRVTAZK), hereafter SUPR4B, 
showed the highest target-specific binding with 86% of the input activity remaining 
bound to the immobilized target and minimal nonspecific binding to the resin alone 
(Figure 1D).  
Binding affinities of SUPR-4B and variants towards LC3A and LC3B 
While SUPR4B appears to serve as a non-canonical LIM, we noted that 
phenylalanine occurred at the first randomized position within the macrocycle.  
Based on known LIM sequences, this residue is likely to interact with the W-site of 
the LC3 hot spot.  Although some LIMs have phenylalanine in this position, it is the 
least commonly occurring amino acid residue (101). Binding to the W-site is 
achieved by burying an aromatic residue into the hydrophobic pocket, and the 
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(1/32) or poor incorporation efficiency at the N-terminus.  Our sequencing may also 
have been too sparse to detect clones with tryptophan at the 2nd position and next-
Figure 2: Binding affinities of SUPR4B peptides. A) Structure of SUPR4B. B) Structure of 
SUPR4B1W. FAM labeled SUPR peptides were incubated with increasing concentrations of 
GST-LC3A and fluorescence polarization measurements were made in triplicate. Each 
measurement was converted to anisotropy and fit to a one-site saturation binding model in 
Graphpad Prism to obtain the equilibrium binding constant. C) SUPR4B binds LC3A with a KD 
= 360 nM D) SUPR4B1W binds LC3A with a KD = 120 nM. E) Atg4B enzyme inhibition assay. 
Increasing concentrations of both SUPR4B and SUPR4B1W impair the ability of Atg4B to 
cleave the C-terminus of LC3-AMC leading to diminished AMC fluorescence. Neither 




generation high throughput sequencing may reveal such clones. we hypothesized 
that substitution of tryptophan for phenylalanine at position 2 in SUPR4B 
(SUPR4B1W) would improve affinity for LC3.  
To evaluate the impact of tryptophan substitution on binding affinity for LC3, 
we measured the binding affinity of both SUPR4B (Figure 2A) and SUPR4B1W 
(Figure 2B) using fluorescence polarization anisotropy. Fluorescein-labeled SUPR 
peptides were incubated with increasing concentrations of GST-LC3A and GST-
LC3B. Fluorescence polarization was measured (λEx =  485 nm, λEm =  528 nm) and 
converted to fluorescence polarization anisotropy which was plotted against 
concentration of protein and fit to a one-site saturation binding model. SUPR-4B1W 
was found to bind to GST-LC3A with a KD of 120 ± 19 nM while SUPR-4B bound to 
GST-LC3A with a KD of 360 ± 83 nM (Figure 2C, D). This data supported our 
prediction that the larger aromatic side-chain of tryptophan would engage more 
strongly with the hydrophobic W-site binding pocket and increase the affinity of 
SUPR4B1W for LC3A relative to SUPR4B. SUPR-4B1W was also found to bind to 
GST-LC3B with a KD of 189 ± 40.1 while SUPR-4B bound to GST-LC3B with a KD of 
392 ± 82.7 nM (Table 1). This indicates that selection against LC3A resulted in 
ligands with similar affinities for the LC3B homolog which is unsurprising given the 
83% residue identity and 90% residue similarity between the two proteins (Clustal 
Omega alignment) 
Binding affinity of both SUPR4B and SUPR4B1W for LC3A is significantly 
enhanced by cyclization. Fluorescence polarization assays were carried out using 
fluorescein-labeled linear SUPR4B and SUPR4B1W. Linear SUPR4B1W was found 
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to bind to GST-LC3A with a KD > 375 nM while linear SUPR4B bound to GST-LC3A 
with a KD > 690 nM. Linear SUPR4B1W was found to bind to GST-LC3B with a KD > 
415 nM while linear SUPR4B bound to GST-LC3B with a KD >335 nM (Table 1). 
These data indicate that cyclization provides at least 0.68 kcal/mol of binding energy 
for SUPR4B1W when interacting with LC3A likely through reduction of 
conformational entropy.   
We also synthesized a version of SUPR4B1W in which the N-methyl-L-
alanine at position 9 was replaced with L-alanine (SUPR4B1W8A) to determine the 
effect of N-methylation on binding affinity.  Fluorescein-labeled SUPR-4B1W8A 
bound to GST-LC3A with a KD of 105 ± 23.2 nM and GST-LC3B with a KD of 197 ± 
52.1 nM. These affinities are very similar to those observed for SUPR4B1W and 
indicate that incorporation of N-methylated amino acids does not positively 
contribute to binding energy in the case of SUPR4B1W.  A summary of binding 
affinities obtained by fluorescence anisotropy is presented in Table 1. 
 LC3A KD (nM) LC3B KD (nM) 
SUPR4B1W Linear > 375 > 415 
SUPR4B1W Cyclic 120 ±19 189 ± 40.1 
SUPR4B Linear > 690 > 335 
SUPR4B Cyclic 360 ± 83 392 ± 82.7 
SUPR4B1W 8A Linear > 1125 > 1250 
SUPR4B1W8A Cyclic 105 ± 23.2 197 ± 52.1 
 




SUPR Peptides Attenuate Atg4b-mediated cleavage of LC3 
Atg4 is a cysteine protease that plays a critical role in the regulation of 
autophagy through post-translational modification of LC3 homologs. Following 
translation, Atg4 binds to LC3 via a LIM and cleaves the protein at the C-terminus to 
expose a glycine residue which is lipidated with phosphatidylethanolamine (PE) prior 
to membrane insertion. We hypothesized that if our SUPR peptides bound to the 
Atg4 LIM-recognizing site on LC3, Atg4 binding and proteolytic cleavage would be 
inhibited.  LC3A bearing a C-terminal 7-amino-3-methylcoumarin moiety (LC3-AMC) 
was pre-incubated with increasing concentrations of SUPR-4B, SUPR-4B1W, or a 
scrambled version of either SUPR peptide. Since AMC is only fluorescent when free 
in solution (λEx = 380 nm, λEm = 460 nm), cleavage of LC3 by Atg4 can be monitored 
by increase in fluorescence at 460 nm. Atg4B (220 pM) was added to each 
combination of LC3-AMC (120 nM) and SUPR peptide (0-100 µM) and fluorescence 
emission was monitored for 40 minutes (Figure 2E). SUPR-4B inhibits Atg4B 
cleavage of LC3-AMC with an apparent Ki > 100 µM while SUPR-4B1W inhibits 
cleavage with apparent Ki ~ 35 µM. Neither scrambled peptide had any inhibitory 
effect on Atg4B cleavage of LC3-AMC indicating that inhibition is sequence-
dependent. These results suggest that the SUPR peptides occupy the PPI hot spot 
of LC3 and prevent formation of the Atg4:LC3 complex leading to inhibition of C-




Protease stability is dependent on cyclization and N-methyl incorporation 
Peptides are highly 
susceptible to proteolysis in 
human serum and this 
feature has compromised the 
translation of many peptides 
into therapeutic compounds.  
SUPR mRNA display 
attempts to mitigate this 
drawback through 
macrocyclization and 
incorporation of N-methyl 
amino acids which have been 
shown to increase biological 
half-lives of peptides by 
orders of magnitude (11). 
We evaluated the 
protease stability of both 
cyclic and linear 
SUPR4B1W and as well as a variant where the N-methyl alanine residues is 
replaced with alanine (SUPR4B1W8A). SUPR peptides were incubated for 
increasing time with agarose-immobilized proteinase-K and subjected to analysis by 
HPLC. SUPR4B1W was found to have a half-life in proteinase-K of 110 minutes, 
Figure 3. Cyclization and N-methyl-L-alanine dramatically improve the 
protease stability of SUPR4B1W. Analytical HPLC experiments show 
that SUPR4B1W has a half-life in proteinase-K of~110 min (red line). 
Without cyclization, linear SUPR4B1W has a half-life of 57 min, a nearly 2-
fold reduction (black line). N-L-methyl alanine plays a crucial role in 
mediating protease resistance; substitution of L-alanine reduces the 
protease half-life of the SUPR peptide to 6 min (blue line). 
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while the linearized version of the peptide was found to have a half-life of 57 minutes 
(Figure 3). Removing the N-methyl-L-alanine dramatically increased susceptibility to 
proteolysis; SUPR-4B1W8A was completely degraded within 60 minutes of 
incubation with proteinase-k (half-life ~ 6 min). Based on these data, it appears that 
N-methyl-L-alanine is a major driver of protease stability, as substitution with L-
alanine completely abrogates resistance to proteinase-K degradation. Previous 
SUPR mRNA display selections suggest that while incorporation of a single N-
methyl amino acid moderately improves protease resistance, dramatic 
improvements in 
protease stability (i.e. 
order of magnitude) 
are driven by multiple 
N-methyl residues 





alanine incorporated at position 8 and the proline at position 2. When considered 
alongside the fluorescence polarization binding data, we can conclude that 
incorporation of N-methyl-L-alanine was primarily driven by selection for protease 
resistance, not selection for binding affinity.  
Figure 5:  SUPR4B1W Selectivity for LC3 Homologs.  A) Crystal structure of 
LC3 (5CX3146) showing the extent of residue conservation between LC3A, 
LC3B, LC3C, GABARAP1, GABARA2, and Atg8.  The W and L sub-sites are 
highly conserved (circled in yellow).  B) SUPR4B1W was immobilized on 
neutravidin-acrylamide an incubated with [35S]-labeled LC3 homologs (LC3A, 
B, and C along with GABARAP L1 and L2, Atg8 (the yeast ortholog of LC3) and 
ubiquitin.  SUPR4B1W showed modest selectivity for LC3A and LC3B 




SUPR4B1W Selectivity for LC3 Homologs 
Fluorescence polarization assays showed that SUPR-4B1W binds to LC3B 
with an affinity similar to that of the selection target, LC3A. This is not entirely 
unsurprising, as LC3A and LC3B share a high degree of sequence similarity, 
particularly in the regions that define the protein-binding hot spot of each protein 
(Figure 4A). We sought to determine whether SUPR4B1W, with its non-canonical 
LIM, exhibits binding for other Atg8 mammalian orthologues or if binding was 
specific for LC3A/LC3B. Open reading frames (ORFs) for LC3A, LC3B, LC3C, 
GABARAP1, GABARAP2, Atg8, and Ubiquitin were transcribed into mRNA in vitro 
and translated in vitro in the presence of [35S]-Methionine. SUPR4B1W was 
biotinylated and immobilized on neutravidin-acrylamide resin and the radiolabeled 
translation products were incubated with the resin. SUPR4B1W showed the highest 
binding to LC3A followed closely by LC3B (Figure 4B), an observation in line with 
our fluorescence anisotropy binding data. Moderate binding was also observed for 
both isoforms of GABARAP as well as Atg8 (the yeast ortholog of LC3).  We 
observed virtually no binding by LC3C, which can be explained by LC3C’s strong 
preference for the LVV motif which is not found in SUPR4B1W(98).  SUPR4B1W 
showed no affinity for ubiquitin suggesting that the peptide binds to the LC3 hot spot 
(defined by the W and L sub-sites) rather than the core ubiquitin fold.  
Autophagy-related proteins that contain canonical LIMs often show affinity for 
multiple isoforms of LC3 as well as isoforms of GABARAP, though affinity for each 
isoform varies (98,146).  There also exists a GABARAP Interacting Motif (GIM)—
(W/F)-(V/I)-X-V—which confers high selectivity for GABARAP proteins(133). Given 
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its small size and non-canonical LIM, the isoform selectivity of SUPR4B1W is very 
much in line with previously described linear LIM peptides. 
SUPR4B1W is internalized into cells and co-localizes with punctate LC3 after 
starvation 
 Before assessing its potential as a therapeutic inhibitor of autophagy, we 
sought to validate the uptake of SUPR4B1W in human cell lines. We utilized copper-
catalyzed click chemistry to conjugate the rhodamine derivative ROX-azide to 
SUPR4B1W via the side chain of a C-terminal propargylglycine residue. HeLa cells 
stably expressing eGFP-LC3B were grown in media supplemented with 
SUPR4B1W-ROX (500 nM) for 24 hours. After 24 hours, cells were starved for 2 
hours to induce autophagy prior to confocal microscopy imaging. Induction of 
autophagy in this cell line results in a diffuse to punctate GFP staining pattern 
reflecting transition of diffuse cytosolic LC3-GFP to autophagosomes.  SUPR4B1W-
ROX is taken up by both unstarved (Figure 5A) and starved (Figure 5B) HeLa- 
  
Figure 6: SUPR4B1W co-localizes with LC3 in starved HeLa cells.  SUPR4B1W-ROX was incubated with 
HeLa cells expressing GFP-LC3 (green)  in normal media (A) or starvation media (B) and visualized by confocal 
fluorescence microscopy.  After starvation, the EGFP-LC3 transitions from diffuse to punctate staining indicating 
induction of autophagy.  Significant overlap (yellow) of red and green puncta in starved cells indicates co-
localization of LC3 and SUPR4B1W inside the cell.  C) M1 and M2 co-localization coefficients were calculated 
for three fields of starved and unstarved cells.  The M2 coefficient (co-localization green signal with red signal) 
increases after starvation. Scale bars represent XX µm. 
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eGFP-LC3 cells, and in both cases displayed a punctate pattern suggesting an 
endocytototic/pinocytotic mechanism of uptake (147). To quantify the extent of 
colocalization between SUPR4B1W-ROX and GFP-LC3 puncta we calculated 
Manders’ M1 and M2 colocalization coefficients for three fields of both starved and 
unstarved cells (Figure 5C). The M1 coefficient gives the percentage of pixels in the 
red channel (SUPR4B1W-ROX) that overlap with pixels in the green channel (eGFP-
LC3).  The M2 coefficient gives the percentage of pixels in the green channel that 
overlap pixels in the red channel.  Starvation increases the M2 coefficient suggesting 
an increased co-localization of LC3 puncta with SUPR4B1W-ROX after starvation-
induced autophagy.  These data support cell uptake of SUPR4B1W and co-
localization with intracellular LC3.   
SUPR peptides sensitize resistant cell lines to cisplatin in vitro.  
One of the overarching goals of this project was to produce cyclic peptide 
autophagy inhibitors that re-sensitized tumors to frontline chemotherapeutics. 
Previous reports have shown that induction of autophagy is correlated with cisplatin 
resistance in many human ovarian cancer cell lines including SKOv3, OVCAR8, 
Hey, CAOv3, and OVCA420. Cisplatin activates extracellular signal-regulated kinase 
(ERK) and promotes autophagy induction (89,148).  Inhibition of MAPK/ERK 
signaling blocks autophagy induction and enhances cisplatin-induced apoptosis. 
This suggests that targeting cisplatin-induced autophagy may be a viable strategy 
for overcoming chemotherapy resistance in ovarian cancer.  
To determine the utility of SUPR4B1W in this context, two platinum-resistant 
epithelial ovarian cancer cell lines—OVCAR8 and HEY—were subjected to 
68 
 
treatment with combinations of cisplatin and SUPR peptide for 48 hours before 
cellular viability was evaluated by MTT assay (Figure 6A, B). In both OVCAR8 and 
















the presence of 
cisplatin in both 
cell lines (p < 
0.0001). In 
OVCAR8 cells, 
Figure 7: SUPR4B1W sensitizes ovarian cancer cells to cisplatin and results in p62 
accumulation and LC3-II/LC3-I perturbation. Treatment of OVCAR8 (A) and HEY (B) 
ovarian cancer cells with SUPR4B1W and cisplatin significantly reduces cell viability after 
48 h relative to cisplatin alone.  A linearized version of SUPR4B1W showed no significant 
effect on viability in the presence or absence of cisplatin.    Incubation of cisplatin-treated 
OVCAR8 cells (C) and Hey cells (D) with SUPR4B1W resulted in accumulation of p62 and 
an increase in the LC3II/LC3I ratio indicating inhibition of autophagy while a scrambled 
version of SUPR4B1W showed no effect.  SUPR4B only showed perturbation of the 
LC3II/LC3I ratio in Hey cells and did not cause accumulation of p62 in either cell line.   
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cisplatin and the cyclic SUPR peptide interacted synergistically to decrease cell 
viability more than either cisplatin alone (p < 0.001) or chloroquine combined with 
cisplatin (p = 0.0002).  Treatment with scrambled SUPR4B1W resulted in no change 
in viability compared to untreated. A linearized version of SUPR4B1W showed no 
significant effects on viability alone or in conjunction with cisplatin (Tukey’s HSD, p > 
0.05).  These data suggest that viability changes are not the result of bulk uptake of 
non-specific peptide into cells, but rather a specific interaction mediated by 
SUPR4B1W. Enhancement of cisplatin efficacy was also seen in other ovarian cell 
lines (SKOV3, OVCAR5), triple-negative breast cancer cell lines (MDA-MB-231), 
and pancreatic cancer cell lines (Mia-PaCa-2, Panc1). These data suggest that 
cyclic SUPR4B1W, rather than a linearized or scrambled version, inhibits autophagy 
in cancer cell lines and sensitizes them to cisplatin-mediated cytotoxicity.  
Western blots of treated cells show that combining cisplatin with both 
SUPR4B1W leads to a dramatic accumulation of lipidated LC3-II and p62 in both 
OVCAR8 and HEY cell lines (Figure 6C, D). Comparatively, the combination of CQ 
and cisplatin induces an accumulation of p62 and a dramatic reduction of cytosolic 
LC3-I and LC3-II.  Cells undergoing autophagy typically show decreased levels of 
p62 as the protein is degraded in the lysosome following autolysosome fusion, and 
accumulation of p62 indicates disruption of autophagic flux(100). Taken together, 
increased p62 and LC3 levels provides a strong indication that SUPR4B1W inhibits 
cisplatin-induced autophagy in cell culture.  Treatment with a scrambled version of 
SUPR4B1W showed no significant effects on p62 accumulation or LC3 lipidation 
indicating that this effect is sequence-dependent.  Notably, SUPR4B showed some 
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effect on the LC3II/LC3I ratio in 
Hey cells but not in OVCAR8.  
SUPR4B showed no effect on p62 
accumulation in either cell line 
which is consistent with its 
reduced LC3 affinity relative to 
SUPR4B1W. 
SUPR4B1W sensitizes OVCAR8 
tumors to carboplatin in nude mice 
Given the encouraging cell-based 
data, we next sought to determine 
if SUPR4B1W could sensitize 
tumors to carboplatin treatment in 
an orthotopic mouse model.  
Cisplatin resistance in ovarian 
cancer is frequently observed in 
recurrent, metastatic nodules that 
appear throughout the 
peritoneum (149). Intraperitoneal 
injection of OVCAR8 cells 
provides a suitable model for 
recurrent, resistant metastatic 
disease in nude mice. When injected, OVCAR8 forms tumor nodules throughout the 
Figure 8:  SUPR 4B1W Inhibits Tumor Growth in vivo. A) 
OVCAR8 cells were injected into the peritoneum of nude mice (n 
= 8 per group) followed by i.p. treatment with carboplatin (25 
mg/kg, 3 times per week), SUPR4B1W (10 mg/kg, 3 times per 
week), or a combination of the two for 3 weeks.  SUPR4B1W + 
carboplatin dramatically reduced tumor mass relative to 
carboplatin alone while SUPR4B1W alone had no effect.  B) The 
same therapeutic trial was carried out for 4 weeks with the 
introduction of a scrambled version of SUPR4B1W.  The 
combination of SUPR4B1W and carboplatin almost completely 
eliminated intraperitoneal growth in 4 weeks while the 
combination of carboplatin and a scrambled peptide showed no 
improvement relative to carboplatin alone. 
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abdominal peritoneum and gastrointestinal tract. To determine the effect of 
SUPR4B1W on tumor nodule formation, nude mice were IP-injected with 2 million 
OVCAR8 cells and subsequently treated 3 times weekly with combinations of 
carboplatin, SUPR4B1W, and chloroquine. At 3 weeks, the mice were sacrificed, the 
tumors were dissected, and total tumor mass for each treatment condition was 
evaluated (Figure 7A). Treatment with SUPR4B1W alone had no impact on tumor 
development (Tukey’s HSD, p = 0.9827), but combining SUPR4B1W with 
carboplatin resulted in a significant reduction in total tumor mass compared to 
treatment with carboplatin alone (Tukey’s HSD, p = 0. 0032). This experiment was 
repeated, extending the treatment period to 4 weeks and treatment with a scrambled 
version of SUPR4B1W (Figure 7B). At 4 weeks, combined SUPR4B1W and 
carboplatin treatment again had a strong effect on tumor growth with 70% of mice in 
the SUPR4B1W+carboplatin group showing no observable tumor development. 
Combining scrambled SUPR4B1W with carboplatin resulted in no difference in total 
tumor mass compared to treatment with carboplatin alone (Tukey’s HSD, p = 
0.9911).   These results provide a strong indication that SUPR4B1W selectively 
inhibits autophagy in tumors and may provide a potent lead compound for future 
therapeutic development.  
Conclusions 
 We have employed SUPR peptide mRNA Display to design SUPR4B1W, a 
potent, cell-permeable inhibitor of the LC3 protein.  This macrocyclic peptide shows 
mid-nanomolar affinity for LC3A and LC3B and selectivity for LC3A/B over other 
Atg8 orthologs.  Binding studies revealed the cyclization contributes modestly, but 
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significantly, to the binding energetics of SUPR4B1W while the non-proteogenic N-
methylalanine is dispensable for affinity.  In contrast, the N-methyl alanine residue is 
absolutely essential for protease resistance while the contribution of cyclization to 
stability is modest.  These results suggest that the incorporation of N-methyl amino 
acids is driven primarily by selection for protease resistance rather than target 
affinity. 
 Fluorophore-tagged SUPR4B1W is readily taken up in HeLa cells and 
displays a punctate staining pattern consistent with endocytosis or pinocytosis.  
While heavily N-methylated cyclic peptides have previously been shown to cross the 
cell membrane by diffusion (139), this mechanism of uptake would presumably have 
resulted in a diffuse staining pattern, particularly in unstarved cells where LC3 is 
distributed evenly throughout the cytosol.  Given the relatively low fraction of N-
methylation (25% of the randomized region) and the presence of an aliphatic 
macrocyclic bridge, we propose that the mechanism of uptake may be similar to that 
of stapled peptides which are also believed to transit the cell membrane by 
endocytosis and/or pinocytosis(150).  While it has also been proposed that stapled 
peptides enter the cell following membrane disruption(151,152), we found no 
evidence of this mechanism by microscopy or by the appearance of non-specific 
toxicity in cell culture and animal models.  Future studies will address the effect of N-
methylation, charge, and hydrophobicity on the mechanism and extent of SUPR 
peptide cell penetration. 
SUPR4B1W sensitizes multiple cell lines to cisplatin treatment and results in 
accumulation of p62 and significant perturbation of the LC3II/LC3I ratio.  These 
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results strongly suggest that SUPR4B1W disrupts the PPIs of LC3 inside the cell 
and inhibits autophagosome maturation.  Accumulation of LC3II, the lipidated form of 
LC3, may indicate that SUPR4B1W inhibits Atg4 binding and subsequent proteolytic 
recycling of LC3II – a conclusion supported by in vitro data showing inhibition of 
Atg4B proteolysis by SUPR4B1W.  Inhibition of LC3II recycling could arrest 
autophagic flux by attenuating the rate of formation of new autophagosomes, 
although this mechanism of action remains to be proven experimentally. 
The combination of SUPR4B1W and carboplatin results in almost complete 
inhibition of tumor outgrowth in vivo suggesting that this compound could be 
administered in an adjuvant setting to enhance the efficacy of platinum-based 
therapies or to prevent the outgrowth of platinum-resistant disease. Although the 
combined effect of SUPR4B1W and cisplatin was also observed in cell culture, the 
effect size was significantly lower relative to the in vivo models.  This divergence 
may be the result of context.  It has previously been shown that induction of 
autophagy in ovarian cancer cell lines results in a strikingly different survival 
phenotype than autophagy induction in the corresponding animal models (80).  This 
was attributed to the effects of a relatively nutrient-poor tumor microenvironment 
compared to the nutrient-rich conditions found in cell culture.  Alternatively the 
striking effect of SUPR peptide/carboplatin combinations in vivo may be the result of 
both chemotherapeutic effects and enhancement of the innate immune system.  
Although athymic nude mice were used to generate the orthotopic models, these 
mice still retain a functional innate immune system(153,154).  Previous work in 
breast cancer (155) and  renal cell carcinoma (RCC) (156) models has shown that 
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autophagy inhibition sensitizes these tumors to natural killer (NK)-mediated cell 
killing by preventing degradation of secreted granzyme.  Inhibition of autophagy in 
macrophages has also been shown to alter polarization from M2 to M1 which could 
facilitate a pro-inflammatory, anti-tumoral response (157).  Future studies will be 
carried out to deconvolute the effect of SUPR peptide-mediated autophagy inhibition 






THE ARHI MODEL OF INDUCIBLE AUTOPHAGY IN OVARIAN CANCER 
This chapter is based in part upon sections of Ornelas, A., McCullough, C.R., Lu, Z. 
et al. Induction of autophagy by ARHI (DIRAS3) alters fundamental metabolic 
pathways in ovarian cancer models. BMC Cancer 16, 824 (2016). 
https://doi.org/10.1186/s12885-016-2850-8 
Introduction 
Aplasia Ras homolog member I (ARHI also known as DIRAS3) is an 
imprinted tumor suppressor gene that is known to exhibit reduced or total loss of 
expression in breast(158), lung (159), hepatocellular (160), and pancreatic (161) 
carcinomas as well as greater than 60% of ovarian carcinomas (80,162). ARHI 
encodes for a small 26 kDa GTPase that is known to have great >50% homology 
with the various isoforms of RAS, a well-studied oncogene that frequently drives 
runaway growth signaling in carcinomas (163). ARHI blocks homodimerization of 
RAS and subsequent downstream growth signaling by forming heterodimers with 
RAS (164). Additionally, ARHI has been shown to inhibit the AKT-PI3K-mTOR 
pathway, the inhibition of which is a known initiator of autophagy. Re-expression of 
ARHI in ovarian carcinoma provides an excellent model of inducible autophagy and 
a powerful tool to study the impact of autophagy on tumor metabolism(80). Re-
expression of ARHI under the control of doxycycline in the ovarian carcinoma cell 
lines SKOv3 and OVCAR8 induces highly elevated levels of autophagic flux 
resulting in non-aptoptotic cell death with 72 hours of induction. We sought to gain a 
better understanding of the impact of ARHI-induced autophagy on metabolic 
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dysfunction and discovered that ARHI-mediated autophagy induces significant 
changes in mitochondrial membrane potential and generation of reactive oxygen 
species (ROS), a potent cellular stressor. When autophagic SKOv3-ARHI and 
OVCAR8-ARHI cell lines are treated with SUPR4B1W—a macrocyclic SUPR 
peptide inhibitor of LC3 PPIs—cell death is no longer observed and cells return to a 
normal viability phenotype at 72 hours post autophagy induction. 
Materials and Methods 
Cell Culture 
ARHI-inducible SKOv3-ARHI ovarian cancer cells were maintained in 
McCoy’s 5A medium supplemented with 10% tetracycline-free fetal bovine serum, 2 
mM L-Glutamine, and 1% (v/v) penicillin-streptomycin. ARHI-inducible OVCAR8-
ARHI ovarian cancer cells were maintained in RPMI 1640 medium supplemented 
with 10% tetracycline-free fetal bovine serum, 2 mM L-Glutamine, 1 mM Na-
Pyruvate, and 1% (v/v) penicillin-streptomycin. 
Uptake of Mitotracker Red FM by Fluorescence Microscopy 
SKOv3-ARHI cells were seeded into 96 well plates and treated with 1µg/ml 
Dox for 48 hours or grown untreated in complete media for 48 hours. Cells were 
treated with 50 nM MitoTracker Red FM (Invitrogen) for 45 minutes in FBS free 
media. Cells were then washed with 1x PBS (Hyclone) and immediately imaged by 
fluorescence microscopy (λex = 581 nm, λem = 644 nm) using a Biotek Cytation5 
Cell Imaging Multi-Mode Reader 
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Uptake of TMRM and H2DCFDA by Flow Cytometry 
SKOv3-ARHI cells were treated with 1 μg/ml Dox for 24 and 48 h or with 50 
nM Rapamycin for 24 h. Cells were then incubated with 20 nM tetramethyl 
rhodamine methyl ester (TMRM) in FBS-free media for 45 min, washed twice with 
phosphate buffered saline, and resuspended in FBS-free media. The mean 
fluorescence intensity for 10,000 cells was obtained by flow cytometry.  
SKOv3-ARHI and SKOv3 (parental) cells were treated with Dox (1 μg/ml) for 
12, 24 and 48 h. In a separate experiment SKOv3-ARHI cells were treated with Dox 
(1 μg/ml) for 48 h with and without BPTES (1 μM). The cells were then washed and 
stained with 5 μM H2DCFDA and analyzed by flow cytometry to obtain the mean 
fluorescence intensity. Triplicate samples were used for each experimental condition 
and analysis of the results was performed in GraphPad. The statistical significance 
was determined by unpaired, two-tailed t-test in GraphPad (*, p < 0.05; **, p < 0.01) 
TOM20 Staining by Flow Cytometry 
SKOv3-ARHI cells were seeded into a 75 cm2 flask and allowed to reach 
confluence. Cells were treated with 1 μg/ mL of Doxycycline for different time points 
as previously discussed. After treatment, cells were trypsinized and harvested at 
500xg for 10 min. Cells were then fixed in 3 % formaldehyde and permeabilized with 
0.1 % Triton X100. Cells were then counted, aliquoted and incubated in 2 μg of 
TOM20 antibody (Santa Cruz Biotechnology) for 40 min. Cells were then washed 
and incubated in F(ab’) 2- Goat anti Rabbit IgH (H + L) Secondary Antibody, Alexa 
Fluor® 488 conjugate (Thermo Scientific). 
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Effect of Autophagy inhibitors on Cellular Viability following ARHI induction 
SKOv3-ARHI and OVCAR8-ARHI cells were seeded into 96-well plates at a 
density of 5,000 cells per well and treated with Dox for 24, 48, or 72 hours or grown 
for 72 hours without Dox treatment. Treatment media was replaced daily. Cells 
underwent simultaneous treatment with SUPR4B1W (50 µM), SUPR4B1W scramble 
(50 µM), Chloroquine (5 µM), or were untreated. Treated cells were give 50 µM 
SUPR4B1W in full media for 24, 48, or 72 hours. After 72 hours, cells were washed 
with 1X PBS and viability was measured by MTT assay. The statistical significance 
of difference in viability was determined by unpaired, two-tailed t-test in GraphPad (*, 
p < 0.05; **, p < 0.01) 
Results and Discussion 
ARHI expression modulates mitochondrial membrane potential & intracellular 
oxidative state 
Staining of SKOv3-ARHI cells with Mitotracker dye following induction of 
ARHI revealed a signficant decrease in dye uptake suggesting a loss of 
mitochondrial membrane potential, potentially induced by depletion of mitochondria 
through autophagic flux (Figure 1A). To quantitate this effect, SKOv3-ARHI cells 
were treated with Dox followed by the Nernstian fluorescent probe TMRM and 
analyzed by flow cytomtery. Uptake of cationic Nernstian probes like TMRM is 
dependent on mitochondrial membrane potential, and the intensity of fluorescence 
generated by the probe can be used as a semi-quantitative measure of 
mitochondrial membrane potential. Treatment with Dox resulted in a decrease in 
TMRM uptake which was most pronounced at 24 h post-induction (Figure 1B). In 
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contrast, treatment with rapamycin had no effect on TMRM uptake. In order to 
determine if low TMRM uptake was being driven by low mitochondiral membrane 
potential or by a decrease in the number of mitochondria, SKOv3-ARHI cells were 
fixed and permeabilized following induction with Dox for 12, 24, and 48 h. The cells 
were then stained for the presence of the TOM20 receptor of the mitochondrial outer 
membrane preprotein translocase and analyzed by flow cytometry. Significantly 
lower Tom20 signal was observed after 12 h of Dox induction suggesting a decrease 
in the mitochondrial mass following ARHI induction (Figure 1C). We also sought to 
determine the effect of ARHI induction on the intracellular oxidative state using the 
oxygen-sensitive dye H2DCFDA. Induction of ARHI was found to increase 
H2DCFDA uptake by flow cytometry by almost 3-fold after 48 h (Figure 1D). This 
result is in good agreement with results of previous work. In contrast, parental 
SKOv3 cells showed no statistically significant change in H2DCFDA following 
treatement with Dox indicating that changes in intracellular redox state were the 
result of ARHI expression. Finally, we measured H2DCFDA uptake following ARHI 
induction and BPTES treatment for 48 h (Figure 1E). BPTES is a selective inhibitor 
of Glutaminase GLS1, a critical component in glutamine metabolism. We found that 
BPTES treatment resulted in decreased H2DCFDA uptake in Dox-induced SKOv3 







Figure 9 ARHI Expression alters Mitochondrial Membrane Potential and ROS in SKOv3-ARHI. A) SKOv3-ARHI 
cells were treated with and without Dox followed by staining with Mitotracker Red FM and visualized by 
fluorescence microscopy at 24 h. B) SKOv3-ARHI cells were treated with Dox or Rapamcyin for the indicated 
times followed by tetramethyl rhodamine methyl ester (TMRM). The mean fluorescence intensity (MFI) was 
obtained by flow cytometry. C) SKOv3-ARHI cells were treated with Dox for 48 h, followed by fixation in 3 % 
paraformaldehyde and permeabilization with 0.1 % Triton X-100. Cells were then stained with TOM20 antibody 
(Santa Cruz Biotechnology) and a secondary goat Anti-rabbit IgG conjugated to AF488® and analyzed by flow 
cytometry D) SKOv3 (parental) and SKOv3-ARHI cells were treated with Dox for the indicated times followed by 
H2DCFDA and analyzed by flow cytometry. The resulting MFI values were normalized to the Dox- value in 
either the parental or ARHI-transfected cell line. E) SKOv3-ARHI cells were treated with Dox for 48 h with and 




Treatment with SUPR4B1W restores viability following ARHI expression 
Induction of ARHI expression in SKOv3-ARHI and OVCAR8-ARHI by addition 
of Dox (1µg/mL) to culture media results in extreme autophagic flux that causes a 
marked reduction in cellular viability within 48 hours. Previous work suggests that 
this cell death occurs through apoptotic and non-apoptotic pathways due to a 
depletion of essential cellular proteins and organelles by autophagy. We sought to 
determine whether inhibition of autophagy following ARHI expression could restore 
cellular viability. As described in Chapter 2, SUPR41BW is a macrocyclic, protease-
resistant peptide that has high affinity and selectivity for LC3.  SUPR4B1W disrupts 
protein-protein interactions (PPIs) necessary for early autophagosome maturation, 
and has shown evidence of enhancing the effect of platinum-based 
chemotherapeutics in models of metastatic, resistant ovarian carcinoma. SKOv3-
ARHI and OVCAR8-ARHI were induced for autophagy for 24, 48, or 72 hours and 
split into groups that received concurrent treatment with SUPR4B1W (50 µM), 
SUPR4B1W scramble (50 µM), Chloroquine (CQ) (5 µM), or no treatment. After 72 
hours, cellular viability was measured by MTT assay. Cells that did not undergo 
autophagy induction showed no change in viability (Figured 2A & 2B) when treated 
with SUPR4B1W or its amino acid sequence scrambled counterpart suggesting that 
treatment with SUPR peptide alone is non-toxic. Treatment with CQ in the absence 
of ARHI induction resulted in a significant reduction in cellular viability in OVCAR8-
ARHI cells after 72 hours of treatment (Figure 2B). CQ is a lysosomtropic agent that 
non-specifically accumulates in acidic vesicles where it raises vesicular pH 
inactivating lysosomal hydrolases. Both SKOv3-ARHI and OVCAR8-ARHI cells 
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demonstrate a return to normal levels of cellular viability at 72 hours post-induction 
when combined with SUPR4B1W treatment (Figure 2C & 2D). Combined treatment 
with scrambled SUPR4B1W or CQ shows no statistically significant restoration of 
viability. Combined treatment of CQ with DOX induction results in reduced cellular 
viability in OVCAR8-ARHI compared to induction alone, which is expected as 
OVCAR8-ARHI cells appear to be sensitive to prolonged CQ treatment even under 
normal growth conditions. While both CQ and SUPR4B1W appear to inhibit 
autophagy, their mechanisms of action differ dramatically. CQ acts late in the 
development of autophagosomes and in fact does not directly impact the autophagy 
machinery at all. CQ only acts after the autophagosome has fused with the 
lysosome to prevent final degradation of the autophagosome’s contents. Those 
contents—such as essential organelles like mitochondria—are still sequestered 
inside vesicles where they cannot carry out their normal cellular functions. Since 
ARHI expression results in cell death due to depletion of essential cytosolic 
machinery by autophagy, it stands to reason that CQ would not restore cellular 
viability since it cannot prevent the sequestration of organelles and proteins. As 
demonstrated in Chapter 2, SUPR4B1W disrupts LC3 PPIs necessary for 
autophagosome maturation both in vitro and in cells. We therefore hypothesize that 
SUPR4B1W impacts early autophagosome formation and maturation preventing 






Inducible ARHI expression in ovarian carcinoma is a unique and powerful 
model that has provided numerous insights into both tumor development and altered 
cancer metabolism. This study has shown that ARHI expression fundamentally 
alters mitochondrial function in ovarian cell lines. We observed both reduced TMRM 
fluorescence and TOM20 signal by flow cytometry following ARHI induction, 
suggesting a decrease in cytosolic mitochondrial mass. Additionally, we observed 
that the generation of ROS increases following ARHI expression.  Both reduced 
mitochondrial mass in the cytosol and increased ROS production could be explained 
Figure 10 MTT assays of cellular viability in the ARHI expression model. A) SKOv3-ARHI and B) OVCAR8-ARHI 
cell lines show no impact on viability from SUPR peptide treatment in the absence of ARHI expression. CQ 
results in a significant reduction in cellular viability in OVCAR8-ARHI after 72 hours of treatment. C) SKOv3-ARHI 
and D) OVCAR8-ARHI cells show restoration of normal viability patterns after 72 hours of ARHI induction 
combined with SUPR4B1W treatment. SUPR4B1W scramble and CQ show no restoration of viability at 72 hours 




if ARHI-induced autophagy is resulting in the sequestration of mitochondria in 
autophagic vesicles and autolysomes where they subsequently become 
dysfunctional.  We hypothesize that this leads to increased ROS burden. 
Interestingly, while both ARHI expression and inhibition of glutamine metabolism 
through BPTES treatment result in increased ROS production, combined Dox and 
BPTES treatment resulted in less ROS production than Dox treatment alone. Further 
studies should focus on why inhibition of glutamine metabolism reduces ROS 
production in the context of ARHI-induced autophagy. 
It has previously been established that ARHI expression leads to significant 
cell death within 48 hours, likely due to depletion of essential cellular machinery 
through highly increased autophagic flux. We demonstrated that treatment with 
SUPR4B1W concurrent with ARHI expression is able to abrogate this loss in cellular 
viability, possibly by disrupting the early formation and maturation of 
autophagosomes through the inhibition of LC3 PPIs. Autophagy inhibitors like CQ 
that disrupt end-stage degradation of autolysosome contents do not restore viability, 
suggesting that they act too late in the autophagic process to rescue viability. 
Further studies will focus on examining the impact of SUPR4B1W on early 
autophagosome development through the use of electron microscopy which is able 
to directly visualize autophagosomes and their contents. Additionally, further studies 
will examine the impact of SUPR4B1W on in vivo models of ARHI expression where 
it is known that ARHI expression results in transition to dormancy rather than cell 
death and increased autophagic flux is thought to be essential in mediating survival 
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Introduction 
High intensity focused ultrasound 
High intensity focused ultrasound (HIFU) is a minimally invasive technique 
that has developed significantly over the last two decades for the treatment of 
benign and malignant conditions in soft tissues (165,166). HIFU treatments use 
ultrasound transducers with highly controlled beams to instantly achieve destructive 
temperatures at their focus. This technique has been used to treat targets that may 
be several centimeters below the skin surface, while preserving healthy tissue since 
hyperthermal therapy tends to occur at the focus of the beam (166). HIFU is of 
clinical interest for several conditions, including atrial fibrillation of cardiac tissue 
(167,168), central nervous system disorders of the brain (169), treatment of both 
benign and malignant solid tumors through thermal ablation (166), and enhanced 
drug delivery at treatment sites (170). In the United States, HIFU has been indicated 




Image guidance is employed during HIFU for treatment planning, tissue 
temperature, and assessment of tissue damage during and after treatment (i.e. 
estimating treatment margins) (166). Real-time image guidance has accommodated 
adaptive ablation planning, leading to increased efficacy of HIFU treatments and 
improved precision in estimating treatment margins (166). Imaging guidance for 
hyperthermal therapy has been provided by magnetic resonance (MRI) imaging, 
computed tomography (CT), and ultrasound (US), all of which have been able to 
elucidate anatomical structures and heating-probe location (172). Several of these 
techniques have demonstrated the capability to monitor tissue temperature changes, 
yet only MRI is used as a standard-of-care technique for image guidance during 
clinical treatments (173,174).  
 
Photoacoustic imaging 
Photoacoustic (PA) imaging is a relatively novel technique that is gaining 
attention due to its feasibility of implementation as a point-of-care imaging solution, 
its molecular sensitivity, and its ready compatibility with existing US technology 
(175). PA imaging can be achieved through extracorporeal or interstitial application 
of near-infrared (NIR) laser pulses, which are absorbed by endogenous 
chromophores or exogenous contrast agents (176,177). Due to the “optical window,” 
in which optical absorption by water, fat, and blood decreases dramatically in the 
NIR region (650-1100 nm), imaging depths of several centimeters can be achieved 
in soft tissues (178). Photon energy absorbed by chromophores is converted into 
mechanical energy through a rapid thermal expansion, which results in the 
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generation of an acoustic transient that propagates through soft tissue and may be 
detected by a standard US transducer at the tissue surface (175,176). Detected 
signals can then be used to estimate a map of optical absorption with sub-millimeter 
spatial resolution. Since PA signals are detected using an ultrasonic transducer, PA 
images can be co-registered with US images (175). These photoacoustic-ultrasonic 
(PAUS) images allow for the presentation of anatomical information alongside 
estimated optical absorption, and thus molecular composition, of the tissue.  
The amplitude of PA pressure waves, 𝑝𝑝0(𝒓𝒓,𝑇𝑇, 𝜆𝜆), generated as a result of 
optical absorption by chromophores in tissue, are dependent on the speed of sound 
in tissue (𝑣𝑣𝑠𝑠(𝑇𝑇) [cm s-1]), a temperature-dependent volume expansion coefficient 
(𝛽𝛽(𝑇𝑇) [K-1]), the isobaric heat capacity in tissue (𝐶𝐶𝑝𝑝(𝑇𝑇) [J kg-1 K-1]), the optical 
absorption coefficient of the tissue (𝜇𝜇𝑎𝑎𝑎𝑎𝑠𝑠(𝒓𝒓, 𝜆𝜆) [cm-1]), and the optical fluence (Φ(𝒓𝒓, 𝜆𝜆) 
[J cm-2]) as (175–177) 
 
𝑝𝑝0(𝑟𝑟,𝑇𝑇, 𝜆𝜆) =  �
𝛽𝛽(𝑇𝑇)𝜈𝜈𝑠𝑠2(𝑇𝑇)
𝐶𝐶𝑝𝑝(𝑇𝑇)
�𝜇𝜇𝑎𝑎𝑎𝑎𝑠𝑠(𝑟𝑟, 𝜆𝜆)Φ(𝑟𝑟, 𝜆𝜆). Eq. 1 
Contrast in PA images arises from variations in the optical absorption 
coefficient, which depends on both the concentration of chromophores in tissue and 
the wavelength of the laser source. Due to the wavelength dependence of the optical 
absorption coefficient, multi-wavelength photoacoustic imaging can be performed by 
varying the wavelength of the laser through the entire NIR region in order to estimate 
the optical absorption properties of the tissue (175,179). Varying the location of the 
PAUS transducer or using a 2D array and obtaining PA signals at several 
wavelengths allows for the generation of a multi-wavelength 3D PAUS volume. 
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Additionally, the temperature dependence of pressure wave generation may allow 
for real-time monitoring and characterization of temperature change during ablation 
(180–183).  
 
Current image-guidance methods 
Image guidance techniques greatly improve the outcome of HIFU treatments 
by allowing physicians to more accurately and completely estimate treatment 
margins, yet existing imaging modalities are not entirely satisfactory for treatment 
guidance (172,184,185). Currently, image guidance of HIFU treatments is performed 
using several standard imaging modalities. Traditional pulse-echo B-mode US 
provides excellent anatomical information and can provide short-term identification 
of hyperechoic regions of tissue corresponding to microbubble formation at the site 
of the HIFU focus; however, it cannot provide quantification of lesion extent (186). 
Elastography can be used to assess and characterize induced lesions, but can be 
difficult to implement in vivo and provide a significant number of false-positives 
(187). Magnetic resonance imaging (MRI) allows for excellent identification of 
treatment targets, treatment planning, and real-time tracking of relative temperature 
changes at the site of ablation through MRI thermography (173,174,188), but it is 
limited by the high cost and equipment incompatibility imposed by high magnetic 
field strengths. PA imaging is a promising modality for image guidance of HIFU 
therapies because of its ready compatibility with existing technology and capability to 
monitor target and healthy tissue during ablation with sub-millimeter spatial 
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resolution. This level of spatial resolution in fact exceeds the spatial resolution of 
existing temperature MRI guidance techniques (1-2 mm) (166,189). 
 
HIFU guidance with PA imaging 
PA imaging provides several unique qualities that make it promising as an 
alternative to existing image-guidance techniques for HIFU. PA imaging is capable 
of both thermography and spectroscopy (180,190,191), allowing for real-time 
assessment of temperature changes and tissue state. In practice, conventional US 
techniques such as Doppler imaging or microbubble-contrast perfusion assessment 
can also be applied concurrently with PA imaging to assess nearby critical 
structures, such as vessels (175).  
Previous studies of HIFU ablations in vitro and in vivo using PA imaging have 
shown that PA imaging is capable of providing image contrast in the ablation region 
(192–197). This change in contrast at the ablation site may be attributed to a change 
in the concentration of chromophores in the tissue as a result of heating (198). 
However, single-wavelength methods typically fail to provide enough information to 
reliably quantify the precise position and dimensions of HIFU lesions. Studies using 
radio-frequency ablation have shown that multi-wavelength PA imaging is capable of 
detecting changes in the concentration of chromophores—specifically in the 
concentration of deoxy-hemoglobin (Hb)—following thermal ablation and that these 
multi-wavelength methods allow PA imaging to identify an optical absorption 
spectrum specific to ablated tissue and distinct from the typical Hb spectrum 
(191,194). In this study, we use the previously described technique (191,194) in an 
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in vitro environment following HIFU and water-bath ablation of cardiac and liver 
tissue samples. 2D and 3D multi-wavelength PA data of ablated tissue samples is 
then correlated to these two absorption spectra to create Tissue Characterization 
Maps (TCM), which are used to quantitate lesion size for comparison to stained 
gross pathology. Additionally, we examine the temperature dependence of the PA 
signal as tissue samples are heated in a PBS bath.   
 
Figure 1. Photographs of experimental equipment. A) LabFUS 2.5-MHz small-animal HIFU 
system. B) Close-up view of eight-element, 2.5-MHz HIFU transducer. C) Vevo LAZR 2100 
combined PAUS imaging system. Red arrow indicates motorized platform for elevation 






Sample preparation and ablation procedure 
Imaging samples were acquired from fresh porcine cardiac and liver tissues 
(Animal Technologies Inc., Tyler, TX) within 24 hours of sacrifice and were never 
frozen. Excised tissues from one liver and two hearts were used to make three liver 
samples and three cardiac samples, each approximately 30x30x20 mm3 in size. 
Each specimen was embedded into an agar phantom for HIFU sonication. The HIFU 
transducer was acoustically coupled to the agar phantoms using ultrasound gel and 
samples were each sonicated for 120 seconds at power settings between 22 and 30 
watts using a LabFUS 2.5-MHz small-animal HIFU system (Image Guided Therapy 
Inc., Paris, France). Photographs of the HIFU system, HIFU transducer, and imaging 
system are presented in Figure 1. Following ablation, tissue specimens were 
removed from their agar phantoms, and the uppermost 1.5 – 2 mm of tissue surface 
was removed in order to expose ablation lesions to allow for tissue-sample 
photography and later co-registration with imaging data. 
Additionally, fresh bovine liver tissues (Animal Technologies Inc., Tyler, TX) 
were acquired within 24 hours of sacrifice and never frozen. Two samples were 
excised from one liver and submerged in normal PBS in an imaging chamber 
containing a heat exchanger. The goal of this experiment was to monitor the tissue 
PA signal as a function of bath temperature. The tissue sample was located in the 
center of the copper tubing coil, which comprised the heat exchanger, to generate 
an approximately isotropic temperature field. Bath temperature was measured via 
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Following the aforementioned ablation procedure, specimens were anchored 
in a thin layer of gelatin and submerged in normal phosphate buffered saline (PBS) 
to achieve acoustic coupling between the tissue sample and the PAUS transducer. 
PAUS imaging was performed using a Vevo LAZR 2100 imaging system equipped 
with a 21-MHz US transducer coupled to a pulsed Nd:YAG laser capable of 
irradiating from 670-970 nm (FUJIFILM VisualSonics Inc., Toronto, Canada). In each 
sample, a single-wavelength 3D PAUS scan was performed over the extent of the 
tissue sample in order to identify a single plane containing the ablation lesion. The 
location of the lesion was chosen by selecting an area in the 3D PAUS scan 
exhibiting a hyperechoic US signal and high PA contrast. After identification of the 
lesion, a 2D comprehensive multi-wavelength PA scan was performed on this plane 
using wavelengths ranging from 680-970 nm in 3-nm steps. A multi-wavelength 3D 
PAUS scan was then performed on each tissue over a volume including the ablation 
lesion using five wavelengths in the NIR region (740, 750, 760, 780, 900 nm), 
corresponding to a distinct feature in the Hb absorption spectrum (199), and 
averaging eight frames for each wavelength and location. 
For the bath-heated samples, multi-wavelength PA imaging was done using 
five wavelengths in the NIR region (740, 750, 760, 770, 780 nm), corresponding to 
the same Hb spectral feature. First, a baseline multi-wavelength PA acquisition was 
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performed. The bath-heat exchanger was then activated, and the tissue bath 
temperature rapidly rose to approximately 60 °C. PA imaging at all wavelengths was 
conducted at one-minute intervals for the first 30 minutes, then at five-minute 
intervals thereafter, up to 60 minutes. Bath temperature was measured at each 
imaging time-point. Immediately post-imaging, the tissue sample was removed from 
the water bath and bisected at the imaging plane. Photographs were taken of the 
sample prior to heating, as well as at the point of bisection post-heating. 
 
Staining procedure 
Following imaging, samples were stained using triphenyl tetrazolium chloride 
(TTC) salts for registration and comparison of gross pathology to PAUS data 
(Sigma-Aldrich Corp., St Louis, MO). TTC is a redox indicator of metabolic activity: 
the white stain accumulates in cells and is oxidized to a deep red color by a variety 
of molecules associated with metabolic activity (200,201). Tissue in the ablation 
region has undergone necrosis and should become white/gray in color, while 
metabolically active healthy tissue outside the ablation region will become a deep 
red. Staining solutions were prepared by dissolving 0.1 mg/ml TTC in normal PBS. 
Tissue samples were submerged in staining solution and incubated at 37° C for 20 
minutes with constant stirring. After staining, tissue samples were patted dry and 
photographed. Bath-heated tissue samples were not stained as the tissue was 




2D multi-wavelength PA analysis 
The comprehensive 2D multi-wavelength scans were analyzed to assess 
whether HIFU treatment results in a change in the PA spectra of tissue. Regions of 
interest (ROI) were selected in areas showing high PA contrast and areas showing 
low PA contrast, corresponding to areas of ablated and non-ablated tissue, 
respectively. The mean PA signal inside each ROI was calculated for each 
wavelength scanned and plotted to display the absorption spectra for ablated (liver 
and cardiac, respectively) and non-ablated tissue (Figure 2).  
 
Figure 2 Results of 2D comprehensive multi-wavelength PA imaging. A) Overlay of single-
wavelength PA data at 710 nm on matched US image. High PA contrast and US hyperechogenicity 
exhibited in area where lesion is expected. B) Plot of mean PA signal in each ROI indicated at each 
wavelength. Mean PA spectrum in areas outside lesion exhibit the characteristic peak of Hb around 
760 nm; peak not seen in area of high PA contrast where lesion is expected. 
 
Creation of tissue characterization maps  
Tissue characterization maps (TCMs) were generated using a correlation-
based algorithm. Reference absorption spectra for ablated and Hb absorbers were 
obtained from the comprehensive multi-wavelength PA data (liver or cardiac, as 
appropriate) using previously described methods (191). The filtered PA data were 
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compared to two reference spectra (i.e. Hb correlation and a distinct ablated 
correlation for each tissue type), resulting in two 3D datasets of Pearson correlation 
coefficients. These two 3D correlation datasets (i.e. Hb correlation coefficients and 
ablated correlation coefficients) were then processed with a simple thresholding 
algorithm. Correlation thresholds of 0.6 were used for both Hb and ablated reference 
spectra. PA voxels were then classified based on the respective thresholds and 
correlation coefficients. Voxels that correlated strongly (i.e. displayed correlation 
coefficients above the threshold) to only one reference spectra were classified 
accordingly (i.e. class 2 for ablated; class 1 for Hb). Voxels that correlated strongly 
to both were classified according to their greatest correlation coefficient. Voxels that 
correlated strongly to neither reference spectra were classified as 0 (no correlation). 
Thus, a trinary 3D TCM was constructed for each PA dataset and compared to 
photographed gross pathology. For the bath-treated tissue samples, an equivalent 
process was employed, save that a correlation threshold of 0.65 was used. A 2D 
TCM was generated at each time point, and the 2D multi-wavelength PA signal was 
examined as a function of time (i.e. thermal exposure).  
 
Image registration and characterization of ablation size 
HIFU 3D TCM data were co-registered with top-view photographs of stained 
gross pathology by manual registration based on corresponding visual landmarks. 
Top-view C-scan TCMs were obtained by taking the mode along the depth axis for 
each voxel at the surface of the TCM volume. Mode calculations were performed 
from a depth 0.184 mm (corresponding to five voxels, which tended to avoid 
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subsurface fluence artifacts) below the surface of the volume to a depth 1.29 mm 
(corresponding to 35 voxels) below the surface. Borders between areas of ablation 
and non-ablation were manually segmented in matched TCMs and pathology 
photographs by three experts, generating three segmentations for each TCM or 
pathology photograph. The segmentations for each TCM or photograph were 
analyzed automatically using MATLAB. Pixel-wise lesion area was calculated from 
each expert-segmentation of corresponding TCM data and gross pathology 
photographs. The mean and standard deviation of lesion areas from the expert 
segmentations were calculated and subsequently converted to physical dimensions 
(mm2). Percent area agreement between gross pathology and TCMs was calculated 
for each tissue sample as  
 % 𝐀𝐀𝐀𝐀𝐀𝐀𝐀𝐀 𝐀𝐀𝐀𝐀𝐀𝐀𝐀𝐀𝐀𝐀𝐀𝐀𝐀𝐀𝐀𝐀𝐀𝐀
= 𝟏𝟏 −  






An SNR analysis was done, comparing SNR up to 8 mm tissue depth, while 
varying the number of averages. A 0.21x0.18 mm2 sliding kernel was used, 
analyzing signal along a depth line located in the center of the ROI shown in Figure 
5A. Additionally, a noise image was acquired (degassed water, no laser irradiation) 
to assess PA image noise at the equivalent depth. Up to 64 averages were used. 
Analysis was done on beam-formed image data, using the following equation 
 









where 𝑷𝑷𝑷𝑷���� and 𝝈𝝈𝒏𝒏𝒏𝒏𝒏𝒏𝒏𝒏𝒏𝒏 denote the ROI mean PA signal and noise standard deviation, 
respectively. The SNR threshold was empirically determined by analyzing the depth, 
and thus corresponding SNR, at which the TCM loses continuity (i.e. the point at 
which the gaps/inconsistencies in the solid TCM regions become as large as or 
greater than the spatial averaging kernel used). 
 
Results 
2D multi-wavelength PA analysis 
Figure 2 displays the results of 2D multi-wavelength PA imaging performed in 
liver tissue. Figure 2A shows an overlay of the single-wavelength PA signal at 710 
nm on its matched US image. ROIs shown in Figure 2A represent the area 
averaged at each wavelength to generate the reference spectra from ablated and 
non-ablated tissue; these spectra are shown in Figure 2B. We expect the dominant 
absorber to be Hb in this wavelength region as the ex vivo tissue samples should be 
oxygen-depleted (178). Non-ablated tissue displays an absorption spectrum that 
agrees well with that of Hb (191) as the characteristic local maximum in the 
absorption spectrum around 760 nm is readily apparent. The absorption spectrum in 
the ROI corresponding to ablated tissue decreases monotonically with increasing 
optical wavelength and does not display the characteristic 760-nm local maximum of 
the Hb absorption spectrum, indicating a likely change in the concentration of Hb 




Lesion area statistics 
TCMs were created by correlating to wavelengths in the region between 740 and 
780 nm; the region where ablated tissue and Hb absorption spectra are most 
distinct. Tissue characterization was achieved at depths up to 3 mm below the 
surface of the tissue, while gross pathology indicated that lesions extend 5-7 mm in 
depth. Examples of 3D TCM volumes overlaid on matching US volumes for liver and 
cardiac tissues are shown in Figure 3.  
Results of area calculations performed on manually segmented lesions in 
both TCMs and gross pathology photographs can be found in Table 1; a 
representative sample image can be found in Figure 4. In TCM volumes, we 
observed areas of tissue bordering the areas of strong ablation correlation that 
correlated poorly to both ablated and non-ablated absorption spectra. These areas 
were segmented in addition to the area that was primarily classified as the lesion 





























93.2% 79.8% 99.9% 99.1% 70.0% 91.7% 




50.6% 72.5% 90.2% 98.3% 70.1% 61.2% 
 
Table 1 Results of area calculations performed on manually segmented lesions in both 
TCMs and gross pathology photographs. 
 
For the bath-heated samples, Figure 5A–E shows a 2D TCM overlaid on co-
registered B-Mode US images for five time points, with a rectangular square 
identifying an ROI for spectral analysis. At baseline (Fig. 5A) strong correlation to 
Hb is observed to approximately 4 mm in depth across the entire width of the tissue 
sample. The depth of this correlation decreases to about 2 mm by 15 minutes (Fig. 
5B). By 30 minutes, a thin layer correlating to ablated tissue can be identified at the 
tissue surface (Fig. 5C). At 45 minutes, 1 – 2 mm of ablated tissue is identified at the 
surface, with only sporadic Hb is identified beneath the surface, and this trend 
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continues at 60 minutes (Fig. 5E). Figure 5F shows a surface plot of the mean PA 
signal of the ROI, normalized to baseline, as a function of wavelength and time. The 
PA signal rapidly increases for the first 5 minutes after heating onset, but still 
maintains the Hb spectral shape (local maximum at 760 nm). Amplitude decreases 
slightly, but spectral shape is maintained until approximately 30 minutes, at which 
point the spectra begins to flatten, correlating more strongly to the ablated reference 
spectra thereafter (as shown by the surface color). Figure 5G allows for better 
comparison of the spectra at prominent time points. Note that at 5 minutes after 
heating onset (bath temperature of 52 °C) a PA signal increase of approximately 
80% from baseline can been seen across all wavelengths. The signal decreases 
slightly, but remains relatively constant at roughly 50% above baseline until about 30 
minutes after heating onset. At 30 minutes, we can see the PA spectrum flattening 
out, and by 45 and 60 minutes, we observe a monotonically decreasing spectrum 
that strongly resembles the ablated reference spectrum for liver.  
 Analysis of TCMs against the SNR results suggests that an SNR of 10 dB is 
generally sufficient for reliable tissue characterization using this method. By 
increasing averages, we found SNR using this method can be improved 
approximately proportional to �# averages,  allowing accurate TCMs at greater 




Figure 3 Renderings of 3D TCM volumes overlaid matching 3D US volumes. A) Full liver sample 3D 
volume rendering and B) cut-away view of 2D frame in the interior of the lesion of the same liver 
volume. C) Full cardiac sample 3D volume rendering and D) cut-away view of 2D frame in the 




In this initial study, we demonstrate that multi-wavelength PA imaging can 
provide estimates of lesion extent with gross pathology area agreement greater than 
79% in liver and greater than 70% in cardiac tissue. As has been shown previously 
(193,197,202) and demonstrated in this study (Figure 2), high PA signal contrast in 
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the ablated lesion center can be obtained using a single laser wavelength. However, 
PA imaging data from a single wavelength tends not to be sufficient to completely 
characterize the extent of 
the ablation lesion. While 
single-wavelength PA 
imaging may be useful to 
perform a quick 3D scan 
and obtain a rough 
identification of the lesion 
center, multi-wavelength 
TCMs provide significantly 
more information about the 
boundaries and extent of 
ablation lesions, as shown 
by comparing figures 2A 
and 3B and 5A–E. 
Focusing on the 
wavelengths where the 
absorption spectra of ablated and non-ablated tissue display different features, multi-
wavelength TCMs were able to identify HIFU ablation lesions in ex vivo cardiac and 
liver tissue and obtain area agreement with gross pathology photographs in excess 
of 70% and with sub-millimeter spatial resolution. TCMs compared well with 
manually segmented gross pathology photographs (minimum 70% area agreement), 
Figure 4 Comparison of gross pathology and TCM data for one liver 
tissue sample. A) Photographed stained gross pathology. Red box 
indicates area of tissue displayed by 2D TCM data. B) Zoomed in 
photograph of stained gross pathology. Manual segmentation of gross 
pathology overlaid in green. C) C-scan 2D TCM plane reconstructed 
from TCM volume for manual segmentation. Blue indicates Hb 
correlation, Red indicates ablated spectrum correlation, black indicates 





PA imaging as a 
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and liver tissues, 
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lesion dimensions. Imaging artifacts immediately at the surface of the tissue were 
observed and are believed to be the result of subsurface photon fluence and 
Figure 5. Comparison of TCMs (same color-coding as previously stated) and spectra 
for sample subjected to PBS-bath thermal treatment: (A) to (E) TCMs overlaid on co-
registered US B-mode image for time-points 0 (baseline), 15, 30, 45, and 60 minutes 
of thermal treatment, respectively. White rectangular box denotes a 1 × 0.5 mm2 ROI 
selected for analysis, maintained at constant depth from tissue surface; (F) surface 
plot of mean PA signal in ROI (normalized to baseline), as a function of wavelength 
and time. Surface color-map represents mean TCM color value across ROI at each 
time-point; (G) PA-signal spectra from F for time-points 0, 5, 15, 30, 45, and 60 
minutes (time-points at 0, 15, 30, 45, and 60 minutes correspond to images A to E, 
respectively). TCM = tissue characterization map; PBS = phosphate buffered saline; 
US = ultrasound; PA = photoacoustic; ROI = regions of interest. 
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refractive index discontinuities between the surface of the tissue and the PBS used 
to couple the tissue to the ultrasound transducer. In our study, these artifacts were 
mitigated when creating 2D TCM images of the top-view plane by using a depth 
0.184 mm below the tissue surface as the starting point for reconstruction of the C-
scan projected views.  
PA based TCMs also underestimated lesion depth in this experiment. Depth 
of PA imaging is limited by scattering of photons which increases the likelihood of 
absorption by chromophores at shallower depths in the tissue. In this experiment, 
imaging depths were limited to no more than 3 mm below the surface of the tissue, 
yet HIFU lesions extended 5-7 mm in depth. Several techniques could be employed 
in order to increase the penetration depth of imaging, including increased photon 
fluence and increased frame averaging to improve the signal-to-noise ratio at depth, 
as discussed below. Interstitial delivery of light by laser fibers also allows for 
significantly deeper light delivery to provide image guidance of treatments on deep-
lying tissues, such as the liver and kidneys (203). By employing these methods, it 
should be possible to extend imaging depth beyond 3 mm in ex vivo experiments. 
Additionally, penetration depth could possibly be improved in in vivo experiments 
due to the fact that tissues will be highly oxygenated. Optical absorption by 
oxygenated hemoglobin is roughly an order of magnitude lower in the NIR spectrum 
than that of Hb (179). This reduction in optical absorption may allow increased 
optical penetration depth while maintaining energy, but it may require re-optimizing 




A noteworthy effect observed in this experiment was the appearance of a ring 
of tissue surrounding the area correlating to ablated tissue in TCMs that did not 
correlate well to either the obtained ablated tissue spectrum or the standard Hb 
spectrum. This effect was observed in both liver and cardiac tissue in our study and 
has been reported in previous studies (191). In cardiac tissues, the area of non-
correlation was not always observed. An example of this effect is seen in Figure 4C, 
where an area of non-correlated tissue (i.e. black) borders the upper area correlating 
highly to ablated tissue (i.e. red) at the core of the lesion. The segmentation region 
containing the region of ablation-correlated (red) and non-correlated (e.g. also 
including the black region extending from 4-6 mm in elevation in Fig. 4C) tissue 
showed better agreement with segmented ablation regions in gross pathology 
photographs than the segmentations of the ablation-correlated region alone. 
Regions of ablation correlation alone tended to underestimate the area extent of 
lesions when compared to gross pathology segmentations. The change in the PA 
spectrum in ablated tissue likely results from hyperthermia-induced changes in the 
Hb chromophore. It is possible that incomplete conversion of Hb occurs at the edge 
of the ablation region due to reduced increase in local temperature as compared to 
the core of the lesion, resulting in an absorption spectrum that did not correlate well 
to either Hb or the lesion core. 
The capacity of PA imaging to assess temperature has been previously 
demonstrated by examining changes in PA amplitude (180,183) . By applying similar 
techniques, we were able to track the relative temperature rise in the bath-heated 
tissue sample during the first several minutes. As shown in Figure 5F, the PA 
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amplitude then decreases slightly after five minutes. We suspect this is primarily a 
result of changes in surface fluence. As can be seen in the B-Mode US images in 
Figure 5, the tissue swells initially (B and C), before contracting partially (D and E). 
This initial tissue swelling is likely the result of increased osmotic pressure in the 
bath, following temperature increase. The swelling is likely to affect and the surface 
fluence, due to a change in separation between the tissue and light emission source. 
The tissue contraction observed in Figure 5D and 5E is likely due coagulation of 
ECM proteins, which concurs with the observed strong correlation of the PA signal to 
the ablated reference spectrum (red region in figures). These results highlight the 
potential complementary nature of PA thermography and multi-wavelength analysis. 
Tissue coagulation may also explain the decrease in PA amplitude after 30 minutes, 
as increased optical scattering following coagulation will reduce fluence, and thus 
PA signal, at greater depths. While these factors confound PA thermography in this 
experiment, these issues may not be as prevalent in clinical applications for several 
reasons. First, tissue hyperthermal therapy typically occurs on the order of several 
seconds to a few minutes and is typically much more spatially localized, which may 
reduce large scale tissue swelling or edema. Lastly, if an optical scattering increase 
within an ROI correlates to a change in the observed PA spectra, as suggested by 
this study, it may serve as a partial endpoint for hyperthermal therapy, rather than a 
mitigating factor to image guidance. Furthermore, if changes in optical fluence and 
absorption can be accounted for (perhaps by collecting some backscattered light for 
diffuse reflectance assessment (204)), PA thermography may be able to quantify 
thermal dose, comparable to what is currently done using MRI thermography.  
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The SNR analysis suggests that roughly 10 dB SNR is necessary for reliable 
TCM analysis. Our particular system showed that, with 64 averages, the SNR up to 
5 mm can be improved to allow for reliable TCM analysis. While increased averaging 
may be prohibitive in some clinical applications, such as cardiac imaging, this 
analysis suggests a baseline to predict TCM accuracy as a function of depth for a 
given application and imaging system. 
 
Future work 
Development of in vivo imaging solutions will be necessary to apply PA 
imaging clinically for guidance of HIFU treatments. Although development of an in 
vivo system for combined HIFU therapy and PAUS imaging will not be a trivial task, 
building upon previous work by Cui et al. (193,195,202) and Prost et al. (205) may 
improve single-device integration, which allows straightforward co-registration of 
HIFU ablation space with PA and US imaging spaces. This would overcome a 
significant hurdle for clinical translation.  
Real-time image guidance remains a currently unrealized goal for developing 
PA imaging systems. While this study used a laser source with a pulse repetition 
frequency (20 Hz) that limited acquisition to near-real-time imaging (five single-
wavelength frames per second, without averaging), commercial laser systems 
operating at kilohertz pulse repetition frequencies are readily available at select 
wavelengths, albeit sometimes with lower pulse energies. These systems may allow 
PA imaging, with proper wavelength selection, to achieve complete real-time image 
guidance exceeding 30 frames per second (191).  
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Corroboration of these results in an in vivo model is necessary in order to 
confirm that the findings reported here are relevant to further clinical application. 
One recent study (192) has reported inconclusive findings, showing that while most 
single-wavelength ex vivo studies reported positive PA contrast in the ablation 
lesion, it is possible to observe negative contrast in ablation lesions in vivo. One 
proposed explanation is that variations in thermal deposition between in vivo and ex 
vivo models may lead to a different distribution of chromophores between the two 
environments. As our method relies upon correlation to multiple laser wavelengths, it 
may be possible to identify a difference in the chromophores present in the ablated 
regions of in vivo and ex vivo models. While the data in this study suggests Hb is 
present in significant quantities before ablation and is significantly reduced following 
ablation, it is not clear which chromophore(s) is generating PA signal in the ablated 
region. Previous work has suggested that increased temperatures during thermal 
therapy may give rise to a variety of hemoglobin derivatives, which may account for 
the observed contrast between normal and ablated tissue (206–208). While 
production of hemoglobin derivatives is often cited as a potential source of contrast 
in ablated tissues, to our knowledge no study has shown definitively that the 
proposed derivatives are produced in significant concentrations in tissue. Studies of 
the thermal unfolding and aggregation process of hemoglobin using 2D infrared 
spectroscopy have shown that thermal degradation is a complex, multi-step process 
that is irreversible once local tissues reach a certain temperature threshold: initial 
destabilizations in the structure of hemoglobin occur at low temperatures between 
30-44° C; complete thermal unfolding occurs between 44-54° C; and irreversible 
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aggregation of the denatured protein occurs at temperatures above 54° C (209). 
This complex, three-stage denaturation process involves several potentially 
irreversible conformation changes in the structure of hemoglobin. Given the 
dependence of protein absorption on the 3D structure of the protein, these 
irreversible, temperature-dependent structural changes in hemoglobin may explain 
the observed elimination of the 760-nm peak in the Hb spectrum in ablated tissue. 
Partial unfolding of Hb may yield a range of different absorption spectra in ablated 
tissues rather than a single absorption spectrum corresponding to a single 
chromophore. This range of unfolding states could explain the observed correlation 
discrepancies at the edges of tissue lesions and could be developed to benchmark 
levels of partial tissue coagulation. In future studies, it would be useful to submit 
samples of ablated and non-ablated tissues to hemopathological and chemical 
assays in order to identify with confidence which chromophores are present and in 
what concentration before and after ablation.  
PA-based temperature monitoring must also account for changes in optical 
absorption and fluence. A previous study (210) monitored the PA signal ratio at two 
different wavelengths during tissue heating, verifying that PA signal variations occur 
consistently across wavelengths until the tissue undergoes a change of state (i.e. 
thermal coagulation), as we observed. By analyzing complementary PA-signal 
amplitude and multi-wavelength techniques used herein with more applicable 
hyperthermia models (RF- and HIFU-hyperthermal therapy using in vivo models), we 
can better evaluate and improve their utility, which is paramount to implementing 





We have demonstrated the feasibility of using multi-wavelength PA imaging to 
create tissue characterization volumes that allow the differentiation of HIFU-induced 
tissue ablation lesions from non-ablated tissue and to estimate the treatment 
margins of tissue ablations in 2D planes in ex vivo cardiac and liver tissue samples 
following a HIFU ablation. Multi-wavelength PA imaging demonstrates that HIFU-
induced hyperthermia results in changes in the Hb absorption spectrum that can be 
leveraged for PA-based segmentation. Multi-wavelength TCMs were used to 
successfully identify lesion size with a greater accuracy than single-wavelength 
methods. Multi-wavelength TCMs agreed with gold-standard stained pathology 
images (70% area agreement) and were able to successfully assess lesion margins 
with a spatial resolution comparable to existing temperature MRI techniques. 
Additionally, we demonstrated the complementary nature of PA thermography and 
multi-wavelength TCMs. Further in vivo experiments concurrent with treatment must 
be performed to assess PA signal changes in living tissues. These results suggest 
that multi-wavelength PA imaging and PA thermography present a promising 
modality for guiding hyperthermia therapies that depend on precise knowledge of 
temperature and lesion extent in order to preserve critical structures. 
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In this dissertation we have discussed the issue of disease-generating 
intracellular protein-protein interactions (PPIs) and the challenges they pose for 
researchers. Traditional small molecule drug design has narrowly focused on a 
particular area of chemical space to produce “druglike” molecules that passively 
diffuse through the cell membrane to inhibit proteins by occupying localized 
hydrophobic binding pockets on the surfaces of proteins, primarily the active sites of 
enzymes. These targets represent only a small portion of disease-generating targets 
however, and drug-like small molecules lack the size to interrupt PPIs when those 
interactions occur through the interface of surfaces that measure hundreds or even 
thousands of square Angstroms. Biologics have addressed this problem, at least in 
part, by virtue of the fact that monoclonal antibodies—which typically mass ~150 
kDa)—have the requisite size to bind to massive protein surface areas and in fact 
are often larger than their targets. Production of monoclonal antibodies is often 
prohibitively expensive however, and the main asset of antibodies—their size—is an 
Achilles heel as it prevents them from accessing intracellular compartments.  
 Peptides occupy a potentially useful region of chemical space between small 
molecules and biologics. At a length of ~5-20 amino acids, therapeutically-releveant 
peptides have masses in the range 500-2500 Da and surface areas >400 Å2. 
Molecules in this range have sufficient size to disrupt many PPIs, yet peptides have 
historically been largely ignored as therapeutic candidates due to issues of stability 
and cell permeability of linear peptides.  In recent decades, technological 
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developments have made great strides in resolving these issues. Lessons learned 
from cell-penetrating peptides and naturally cell permeable cyclic peptides like 
Cyclosporine A have made it clear that elimination of hydrogen bond donors in the 
peptide backbone and stabilization of the peptide structure through cyclization are 
key properties inherent to stable, cell-permeable peptides. Backbone stabilization—
through macrocyclization or stapling—and incorporation of N-methylation of 
backbone amides are now common design choices that produce serum stable 
peptides often capable of accessing the cytosol. Directed evolution technologies like 
mRNA display are able to efficiently screen massive libraries of peptides—far larger 
by orders of magnitude than any small molecule screen—to produce molecules that 
bind targets and disrupt PPIs with affinity and selectivity comparable to antibodies. 
Technological advancements in mRNA display technology, notably SUPR peptide 
mRNA display, incorporate N-methylation, macrocyclization, and protease screens 
produce serum stable peptides that retain superior binding properties. Excitingly, 
many of the features that impart protease resistance are now known to facilitate cell 
permeability, opening the door to the deployment of SUPR peptide mRNA display as 
a design tool to develop new compounds that target intracellular PPIs. 
 In this dissertation, we have described SUPR mRNA display selections 
against LC3, a small ubiquitin-like protein that plays a crucial role in autophagy. The 
lead candidate from these selections, SUPR4B1W, bound to LC3 with a mid-
nanomolar affinity and showed specificity for the LC3A and LC3B isoforms of LC3. 
SUPR4B1W disrupts interactions between LC3 and the autophagy related protein 
Atg4b in vitro and has a biological half-life of approximately 2 hours in the presence 
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of the highly active protease, Proteinase K.  Evidence of autophagy inhibition was 
observed in two different models of ovarian cancer treated with SUPR4B1W. 
SUPR4B1W 
rescued viability in 
the DIRAS3 model 








not. These data, 
along with 
evidence that 
SUPR4B1W inhibits Atg4B activity in vitro, suggest that SUPR4B1W may inhibit the 
early autophagy machinery and frustrate autophagosome formation. In models of 
autophagy-induced cisplatin resistance, treatment with SUPR4B1W re-sensitized 
ovarian cancer cells to cisplatin causing a significant reduction in cellular viability 
compared to treatment with cisplatin alone. Treatment with SUPR4B1W, in 
combination with cisplatin, also effectively prevented outgrowth of tumor nodules in 
Figure1.  3D structure of SUPR4B1W.  One of the conformational ensemble 
structures reveals that Arg5 side chain forms multiple internal hydrogen bonds with 
several other residues including the backbone carbonyl oxygens of Ala8, Lys10 and 





nude mice four weeks after intraperitoneal injection with an ovarian carcinoma cell 
line.  
 Until now, development of autophagy inhibitors has relied on the directed 
evolution of naïve libraries. Future work on SUPR peptides targeting LC3 will focus 
on rational design and optimization using predictive modeling of the structure of 
SUPR4B1W to determine the mechanism of its interactions with LC3.  
Our collaborators the 
laboratory of Shuxing Zhang have 
generated structural models of 
potential conformers of 
SUPR4B1W. Using this method, 
the Zhang lab demonstrated that 
the side-chain of Arg5 in 
SUPR4B1W forms multiple 
internal hydrogen bonds with 
several other amino acids in the 
peptide (Figure 1). These internal 
hydrogen bonds may contribute strongly to both the stability and cell permeability of 
SUPR4B1W.  
To model SUPR peptide – LC3 interactions, the LC3A crystal structure 
(PDB:5CX3) was imported into MOE software. Preliminary modeling based on the 
initial preposition of SUPR4B1W in the binding pocket of LC3, indicates that the 
Figure 2: Preliminary computational models of SUPR4B1W 
docked into the active sites of LC3. Green surface represents 
hydrophobic areas on LC3, blue for electrostatic positive and 
red for negative. 
116 
 
Pro3 facilitates formation of beta turn involving residues His4, Arg5, and Val6 
(Figure 2). Such beta turn structure explains how SUPR4B1W can accommodate an 
extra residue between the W-site and L-site binding residues as well as enhanced 
affinity relative to peptides lacking proline at the third position. Moreover, this model 
supports our hypothesis that the Trp2 side chain interacts with W site and the side 
chain of Val6 interacts 
with L site.  Interestingly, 
the imidazole side chain 
of His4 stacks with the 
side chain of His27 in 
LC3, potentially 
contributing to the biding 
energy of the cyclic 
peptide. Modeling of the 
linearized version of 
SUPR4B1W provides some insight into why cyclization improves binding (Figure 3). 
Without the beta turn imposed by cyclization and Pro3, the linear peptide struggles 
to accommodate the addition of a third spacer amino acid to the LIM and presents 
Arg4 in the L-site rather than Val5. These observations provide structural evidence 
to explain the higher affinity of cyclized SUPR4B1W relative to the linear version. 
Modeling of the selected SUPR4B peptide (phenylalanine at position 2) predicts a 
significantly weaker binding energy which we observe experimentally. 
Figure 3 preliminary modeling of SUPR4B1W linear predicts that without the 
beta turn imposed by proline in the cyclic conformation, it is difficult for Val6 
to associate with the L-site resulting in reduced affinity 
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 In the future, we will carry out computational alanine scans to gain knowledge 
about the impact of specific residues on the conformation of SUPR4B1W and its 
interaction with LC3. By computationally mutating individual residues of SUPR4B1W 
to alanine and docking the new structure into LC3, we can better understand the 
impact of specific amino acid residues.  This data will inform future medicinal 
chemistry efforts to drive the affinity of SUPR4B1W into the low nanomolar regime. 
Preliminary computational alanine scanning indicates that mutation of Trp2 or Val6 
significantly reduces the affinity to LC3, a prediction that is entirely consistent with 
our experimental data.  Mutating Trp2 to Ala results in maximum affinity reduction 
while mutating Val6 to Ala results in second highest reduction in affinity. 
Interestingly, mutating Arg5 to Ala resulted in increase in affinity. The models show 
that Arg5 does not interact with LC3 receptor and is instead involved in forming 
multiple hydrogen bond interactions with backbone carbonyl oxygen atoms.  We 
speculate that replacing such Arg with Ala may contribute to increased affinity for 
LC3 while decreasing its cell permeability through the disruption of the 
intramolecular hydrogen bond network.  Further modeling can help identify amino 
acid substitutions that may convey improved properties such as binding affinity or 
specificity for individual isoforms of LC3. 
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